Gezondheidszorg
916 bedrijven in 30 branches · totale beurswaarde $11,92 bln
Mediane omzetgroei
9,3%
Mediane operationele marge
−35,8%
Mediane FCF-marge
−15,4%
Mediaan rendement op kapitaal
1,8%
Mediane K/W
17,6x
Pharmaceutical Preparations · 409
| Bedrijf | Beurswaarde | Omzet | Groei | Oper. marge | ROIC | K/W | Dag |
|---|---|---|---|---|---|---|---|
| Nanobiotix S.A. NBTX | $1,40 bln | $36,8 mln | — | −33,2% | — | — | 0,6% |
| Akari Therapeutics Plc AKTX | $1,18 bln | — | — | — | — | — | 1,5% |
| BeOne Medicines Ltd. ONC | $568,5 mld | $5,3 mld | 40,2% | 8,4% | 46,7% | — | 1,2% |
| Novo Nordisk A S NVO | $173,7 mld | $46,7 mld | 10,9% | 41,3% | 32,2% | 11,2x | 1,0% |
| Royalty Pharma plc RPRX | $35,6 mld | $2,4 mld | 5,1% | 65,6% | 8,7% | 34,1x | 0,2% |
| Alnylam Pharmaceuticals, Inc. ALNY | $31,0 mld | $3,7 mld | 65,2% | 13,5% | — | 96,2x | 1,4% |
| Zai Lab Ltd ZLAB | $26,8 mld | $460 mln | 15,3% | −49,9% | −78,6% | — | 9,0% |
| INSMED Inc INSM | $20,3 mld | $606 mln | 66,7% | −205,6% | — | — | 1,8% |
| BridgeBio Pharma, Inc. BBIO | $13,4 mld | $502 mln | 126,3% | −104,2% | — | — | 0,6% |
| Madrigal Pharmaceuticals, Inc. MDGL | $12,7 mld | $958 mln | 432,1% | −31,3% | — | — | 4,2% |
| Summit Therapeutics Inc. SMMT | $12,0 mld | — | — | — | — | — | 0,5% |
| Protagonist Therapeutics, Inc PTGX | $9,8 mld | $46,0 mln | −89,4% | −343,6% | — | 134,4x | 0,8% |
| Tg Therapeutics, Inc. TGTX | $8,5 mld | $616 mln | 87,3% | 20,0% | 16,4% | 19,8x | 1,9% |
| Axsome Therapeutics, Inc. AXSM | $7,5 mld | $638 mln | 65,5% | −26,1% | — | — | 7,1% |
| Praxis Precision Medicines, Inc. PRAX | $7,4 mld | $0,0 mln | −100,0% | — | — | — | 2,3% |
| Ionis Pharmaceuticals Inc IONS | $7,1 mld | $944 mln | 33,8% | −40,4% | — | — | 2,2% |
| Kiniksa Pharmaceuticals International, plc KNSA | $6,3 mld | $678 mln | 60,1% | 11,4% | — | 84,3x | 5,0% |
| Rhythm Pharmaceuticals, Inc. RYTM | $6,1 mld | $190 mln | 45,8% | −101,2% | — | — | 1,8% |
| Veradermics, Inc MANE | $5,6 mld | — | — | — | — | — | 0,2% |
| Ptc Therapeutics, Inc. PTCT | $5,6 mld | $1,7 mld | 114,5% | 50,1% | — | — | 3,9% |
| Cogent Biosciences, Inc. COGT | $5,3 mld | — | — | — | — | — | 0,3% |
| Mirum Pharmaceuticals, Inc. MIRM | $5,1 mld | $521 mln | 54,7% | −4,2% | — | — | 3,3% |
| Amarin Corp Plc\Uk AMRN | $4,9 mld | $214 mln | −6,5% | −23,5% | — | — | 1,6% |
| Travere Therapeutics, Inc. TVTX | $4,7 mld | $491 mln | 110,5% | −12,8% | — | — | 4,5% |
| Structure Therapeutics Inc. GPCR | $4,6 mld | — | — | — | — | — | 3,4% |
| Erasca, Inc. ERAS | $4,5 mld | — | — | — | — | — | 2,5% |
| Liquidia Corp LQDA | $4,3 mld | $158 mln | 1.031,2% | −32,5% | — | 30,5x | 7,5% |
| Dianthus Therapeutics, Inc. /DE/ DNTH | $4,3 mld | $2,0 mln | −67,3% | −8.739,3% | — | — | 2,2% |
| Arcutis Biotherapeutics, Inc. ARQT | $4,2 mld | $376 mln | 91,3% | −3,3% | −12,5% | 141,8x | 3,1% |
| Edgewise Therapeutics, Inc. EWTX | $4,2 mld | — | — | — | — | — | 1,7% |
| Organon & Co. OGN | $3,7 mld | $6,2 mld | −2,9% | — | — | 17,6x | 0,0% |
| AbCellera Biologics Inc. ABCL | $3,6 mld | $75,1 mln | 160,6% | −289,0% | — | — | 4,0% |
| Xenon Pharmaceuticals Inc. XENE | $3,5 mld | $7,5 mln | — | −4.974,3% | — | — | 3,2% |
| Tango Therapeutics, Inc. TNGX | $3,5 mld | $62,4 mln | 48,3% | −178,4% | — | — | 16,4% |
| IDEAYA Biosciences, Inc. IDYA | $3,2 mld | $219 mln | 3.024,4% | −72,8% | — | — | 3,9% |
| Gossamer Bio, Inc. GOSS | $3,2 mld | $48,5 mln | −57,7% | −352,2% | — | — | 1,5% |
| Amylyx Pharmaceuticals, Inc. AMLX | $3,0 mld | $0,0 mln | −100,0% | — | — | — | 4,8% |
| Nurix Therapeutics, Inc. NRIX | $2,9 mld | $84,0 mln | 54,0% | −340,2% | — | 11,0x | 0,7% |
| Disc Medicine, Inc. IRON | $2,9 mld | — | — | — | — | — | 0,7% |
| Viking Therapeutics, Inc. VKTX | $2,8 mld | $0,0 mln | — | — | — | — | 5,5% |
| Silence Therapeutics plc SLN | $2,8 mld | $0,6 mln | −98,7% | −16.292,8% | — | — | 0,1% |
| Enliven Therapeutics, Inc. ELVN | $2,7 mld | — | — | — | — | — | 1,0% |
| Dyne Therapeutics, Inc. DYN | $2,6 mld | — | — | — | −3.526,6% | — | 1,0% |
| Precigen, Inc. PGEN | $2,6 mld | $9,7 mln | 146,7% | −1.141,1% | −538,0% | — | 3,1% |
| NewAmsterdam Pharma Co N.V. NAMS | $2,4 mld | $22,5 mln | −50,6% | −1.002,9% | — | — | 8,7% |
| Supernus Pharmaceuticals, Inc. SUPN | $2,4 mld | $719 mln | 8,6% | −8,7% | — | — | 3,3% |
| Arcus Biosciences, Inc. RCUS | $2,3 mld | $247 mln | −4,3% | −156,3% | — | — | 4,2% |
| MBX Biosciences, Inc. MBX | $2,3 mld | — | — | — | — | — | 3,9% |
| Prestige Consumer Healthcare Inc. PBH | $2,3 mld | $1,1 mld | −4,3% | 28,4% | 8,1% | 13,4x | 3,4% |
| Aurinia Pharmaceuticals Inc. AUPH | $2,3 mld | $283 mln | 20,4% | 37,1% | — | 7,4x | 2,7% |
| PERRIGO Co plc PRGO | $2,2 mld | $4,3 mld | −2,8% | −26,4% | −14,6% | — | 2,5% |
| Agios Pharmaceuticals, Inc. AGIO | $2,2 mld | $54,0 mln | 48,0% | −873,9% | — | — | 0,5% |
| SELLAS Life Sciences Group, Inc. SLS | $2,2 mld | — | — | — | — | — | 1,7% |
| Biohaven Ltd. BHVN | $2,1 mld | — | — | — | — | — | 5,5% |
| Zymeworks Inc. ZYME | $2,1 mld | $106 mln | 38,9% | −87,3% | — | — | 0,8% |
| Immunome Inc. IMNM | $2,0 mld | $6,9 mln | −23,2% | −3.228,8% | — | — | 1,5% |
| Vera Therapeutics, Inc. VERA | $2,0 mld | — | — | — | — | — | 3,6% |
| Trevi Therapeutics, Inc. TRVI | $2,0 mld | — | — | — | — | — | 2,6% |
| Xencor Inc XNCR | $1,9 mld | $126 mln | 13,7% | −141,4% | −20,0% | — | 2,6% |
| Sarepta Therapeutics, Inc. SRPT | $1,9 mld | $2,2 mld | 15,6% | −31,8% | −53,7% | — | 2,5% |
| Septerna, Inc. SEPN | $1,8 mld | $46,0 mln | 4.174,5% | −148,6% | — | — | 1,1% |
| Schrodinger, Inc. SDGR | $1,8 mld | $256 mln | 23,3% | −65,2% | — | — | 5,3% |
| Palvella Therapeutics, Inc. PVLA | $1,8 mld | $2,6 mln | 303,4% | −1.490,4% | — | — | 1,0% |
| Xeris Biopharma Holdings, Inc. XERS | $1,8 mld | $292 mln | 43,7% | 8,5% | 20,2% | — | 6,1% |
| Mineralys Therapeutics, Inc. MLYS | $1,7 mld | — | — | — | — | — | 4,3% |
| Zenas BioPharma, Inc. ZBIO | $1,7 mld | $10,0 mln | 100,0% | −3.830,6% | — | — | 4,8% |
| Stoke Therapeutics, Inc. STOK | $1,7 mld | $184 mln | 404,5% | −11,2% | — | — | 2,6% |
| Eton Pharmaceuticals, Inc. ETON | $1,6 mld | $80,0 mln | 104,9% | −1,1% | −1,7% | — | 0,0% |
| Ultragenyx Pharmaceutical Inc. RARE | $1,6 mld | $673 mln | 20,2% | −79,5% | — | — | 1,9% |
| Phibro Animal Health Corp PAHC | $1,6 mld | $1,5 mld | 17,1% | 12,8% | — | 16,0x | 2,5% |
| COMPASS Pathways plc CMPS | $1,5 mld | — | — | — | — | — | 3,9% |
| Omeros Corp OMER | $1,5 mld | — | — | — | — | 9,6x | 1,7% |
| Anaptysbio, Inc ANAB | $1,5 mld | $235 mln | 157,0% | 96,7% | — | — | 1,3% |
| Pacira BioSciences, Inc. PCRX | $1,5 mld | $726 mln | 3,6% | 2,6% | 1,5% | 101,2x | 0,2% |
| Ocular Therapeutix, Inc OCUL | $1,5 mld | $52,0 mln | −18,5% | −519,8% | — | — | 1,7% |
| Oric Pharmaceuticals, Inc. ORIC | $1,4 mld | — | — | — | — | — | 3,4% |
| uniQure N.V. QURE | $1,4 mld | $16,1 mln | −40,6% | −1.151,4% | −76,8% | — | 2,9% |
| Ascentage Pharma Group International AAPG | $1,4 mld | $79,9 mln | −41,4% | — | — | — | 3,5% |
| Tyra Biosciences, Inc. TYRA | $1,3 mld | — | — | — | — | — | 2,0% |
| Damora Therapeutics, Inc. DMRA | $1,3 mld | $1,2 mln | 38,3% | −18.069,6% | — | 2,8x | 2,9% |
| Opko Health, Inc. OPK | $1,2 mld | $607 mln | −14,9% | −19,3% | −7,4% | — | 0,0% |
| Rapport Therapeutics, Inc. RAPP | $1,2 mld | — | — | — | — | — | 2,3% |
| Nektar Therapeutics NKTR | $1,2 mld | $55,2 mln | −43,9% | −253,7% | — | — | 3,7% |
| Syndax Pharmaceuticals Inc SNDX | $1,2 mld | $172 mln | 627,8% | −158,4% | −59,2% | — | 1,3% |
| Lb Pharmaceuticals Inc LBRX | $1,2 mld | — | — | — | — | 1,7x | 1,8% |
| Bicara Therapeutics Inc. BCAX | $1,2 mld | — | — | — | — | — | 3,1% |
| GH Research PLC GHRS | $1,1 mld | — | — | — | −143,4% | — | 2,3% |
| Maravai Lifesciences Holdings, Inc. MRVI | $1,1 mld | $186 mln | −28,3% | −115,9% | −59,2% | — | 3,5% |
| Savara Inc SVRA | $1,1 mld | — | — | — | — | — | 7,0% |
| Harrow, Inc. HROW | $1,1 mld | $272 mln | 36,4% | 11,2% | 10,5% | — | 1,0% |
| Janux Therapeutics, Inc. JANX | $1,0 mld | $10,0 mln | −5,6% | −1.576,7% | — | — | 2,3% |
| Verastem, Inc. VSTM | $1,0 mld | $30,9 mln | 209,1% | −550,3% | — | — | 0,2% |
| ArriVent BioPharma, Inc. AVBP | $1.000 mln | — | — | — | — | — | 9,4% |
| Mannkind Corp MNKD | $986 mln | $349 mln | 22,2% | 11,1% | 29,3% | — | 0,3% |
| Corvus Pharmaceuticals, Inc. CRVS | $973 mln | — | — | — | — | — | 1,1% |
| Rigel Pharmaceuticals Inc RIGL | $942 mln | $294 mln | 64,1% | 42,6% | 43,4% | 2,8x | 1,5% |
| Alto Neuroscience, Inc. ANRO | $941 mln | — | — | — | — | — | 1,0% |
| Cryoport, Inc. CYRX | $907 mln | $176 mln | 12,4% | −20,9% | — | — | 0,8% |
| Jade Biosciences, Inc. JBIO | $891 mln | — | — | — | — | 1,7x | 2,1% |
| MoonLake Immunotherapeutics MLTX | $876 mln | — | — | — | — | — | 4,0% |
| Alumis Inc. ALMS | $866 mln | $24,1 mln | — | −1.886,9% | — | — | 0,6% |
| Kura Oncology, Inc. KURA | $854 mln | $67,5 mln | 25,2% | −449,9% | — | — | 2,5% |
| Pharming Group N.V. PHAR | $836 mln | $376 mln | 26,6% | 6,9% | — | — | 5,0% |
| Arbutus Biopharma Corp ABUS | $829 mln | $14,1 mln | 128,2% | −271,0% | — | 5,3x | 0,2% |
| Climb Bio, Inc. CLYM | $776 mln | — | — | — | — | — | 3,3% |
| Ardelyx, Inc. ARDX | $764 mln | $407 mln | 22,1% | −10,1% | −30,8% | — | 3,8% |
| Annexon, Inc. ANNX | $754 mln | — | — | — | — | — | 1,6% |
| CorMedix Inc. CRMD | $726 mln | $312 mln | 617,0% | 48,2% | — | 3,6x | 3,1% |
| Shattuck Labs, Inc. STTK | $712 mln | $1,0 mln | −82,5% | −5.150,8% | — | — | 2,0% |
| Inventiva S.A. IVA | $693 mln | $5,1 mln | −49,2% | −3.145,5% | — | — | 3,1% |
| Olema Pharmaceuticals, Inc. OLMA | $670 mln | — | — | — | — | — | 8,7% |
| Wave Life Sciences, Inc. WVE | $649 mln | $42,7 mln | −60,5% | −504,1% | — | — | 5,1% |
| Design Therapeutics, Inc. DSGN | $640 mln | $0,0 mln | — | — | — | — | 2,4% |
| Lexicon Pharmaceuticals, Inc. LXRX | $621 mln | $49,8 mln | 60,2% | −98,2% | −59,2% | — | 4,7% |
| Cypherpunk Technologies Inc. CYPH | $613 mln | — | — | — | — | 5,0x | 5,4% |
| Zevra Therapeutics, Inc. ZVRA | $602 mln | $106 mln | 350,9% | −59,1% | −236,3% | 10,4x | 5,0% |
| Gyre Therapeutics, Inc. GYRE | $589 mln | $117 mln | 10,2% | 9,9% | — | — | 0,2% |
| Puma Biotechnology, Inc. PBYI | $580 mln | $228 mln | −0,9% | 16,3% | 58,4% | 21,2x | 2,1% |
| Ironwood Pharmaceuticals Inc IRWD | $578 mln | $296 mln | −15,7% | 33,3% | — | 4,5x | 3,1% |
| Aclaris Therapeutics, Inc. ACRS | $535 mln | $7,8 mln | −58,2% | −975,9% | — | — | 2,1% |
| Neurogene Inc. NGNE | $531 mln | $0,0 mln | −100,0% | — | — | — | 3,0% |
| Immix Biopharma, Inc. IMMX | $520 mln | — | — | — | — | — | 2,4% |
| Sagimet Biosciences Inc. SGMT | $509 mln | — | — | — | — | — | 3,7% |
| CytomX Therapeutics, Inc. CTMX | $508 mln | $76,2 mln | −44,8% | −29,3% | — | — | 4,9% |
| Aquestive Therapeutics, Inc. AQST | $500 mln | $44,5 mln | −22,6% | −159,5% | — | — | 3,1% |
| Phathom Pharmaceuticals, Inc. PHAT | $481 mln | $175 mln | 216,9% | −91,4% | — | — | 18,1% |
| Arvinas, Inc. ARVN | $480 mln | $263 mln | −0,3% | −45,1% | — | 30,4x | 5,4% |
| Nuvectis Pharma, Inc. NVCT | $471 mln | — | — | — | — | — | 4,0% |
| Evolus, Inc. EOLS | $462 mln | $297 mln | 11,6% | −11,0% | −37,3% | — | 5,4% |
| Prothena Corp Public Ltd Co PRTA | $428 mln | $9,7 mln | −92,8% | −2.216,4% | — | — | 0,6% |
| Benitec Biopharma Inc. BNTC | $403 mln | — | — | — | — | — | 1,9% |
| Rezolute, Inc. RZLT | $401 mln | — | — | — | — | — | 0,1% |
| ARS Pharmaceuticals, Inc. SPRY | $400 mln | $84,3 mln | −5,5% | −212,9% | — | — | 6,7% |
| Altimmune, Inc. ALT | $393 mln | $0,0 mln | 105,0% | −230.461,0% | — | — | 2,3% |
| Opus Genetics, Inc. IRD | $387 mln | $14,2 mln | 29,1% | −271,9% | — | — | 9,2% |
| Assembly Biosciences, Inc. ASMB | $374 mln | $72,3 mln | 153,5% | −16,8% | — | 16,4x | 2,2% |
| Relmada Therapeutics, Inc. RLMD | $367 mln | — | — | — | — | — | 0,6% |
| Indaptus Therapeutics, Inc. INDP | $367 mln | — | — | — | — | — | 5,7% |
| MapLight Therapeutics, Inc. MPLT | $362 mln | — | — | — | — | 0,2x | 3,4% |
| Prelude Therapeutics Inc PRLD | $357 mln | $12,1 mln | 73,4% | −861,3% | — | — | 0,8% |
| Helus Pharma Inc. HELP | $355 mln | — | — | — | — | — | 3,0% |
| Capricor Therapeutics, Inc. CAPR | $344 mln | $0,0 mln | −100,0% | — | — | — | 3,3% |
| Enanta Pharmaceuticals Inc ENTA | $339 mln | $65,3 mln | −3,4% | −130,7% | — | — | 0,2% |
| Adlai Nortye Group Ltd. ANL | $338 mln | $5,0 mln | — | −714,0% | −343,8% | — | 0,0% |
| Atea Pharmaceuticals, Inc. AVIR | $323 mln | — | — | — | — | — | 0,2% |
| Emergent BioSolutions Inc. EBS | $321 mln | $743 mln | −28,8% | 13,5% | 7,2% | — | 0,0% |
| Immunic, Inc. IMUX | $315 mln | — | — | — | — | 3,6x | 2,6% |
| Contineum Therapeutics, Inc. CTNM | $311 mln | — | — | — | — | — | 1,0% |
| Turn Therapeutics Inc. TTRX | $306 mln | — | — | — | — | — | 1,0% |
| Avalo Therapeutics, Inc. AVTX | $302 mln | $0,1 mln | −86,6% | −123.601,7% | — | — | 7,0% |
| Fulcrum Therapeutics, Inc. FULC | $281 mln | $0,0 mln | −100,0% | — | — | — | 0,0% |
| Arcturus Therapeutics Holdings Inc. ARCT | $280 mln | $82,0 mln | −46,1% | −93,0% | — | — | 8,3% |
| Whitehawk Therapeutics, Inc. WHWK | $266 mln | $7,1 mln | −72,5% | −1.601,1% | — | — | 1,2% |
| Rocket Pharmaceuticals, Inc. RCKT | $262 mln | $0,0 mln | — | — | — | — | 0,9% |
| Eledon Pharmaceuticals, Inc. ELDN | $261 mln | — | — | — | — | — | 0,0% |
| Abeona Therapeutics Inc. ABEO | $251 mln | $5,8 mln | — | −1.536,9% | — | — | 1,6% |
| Bicycle Therapeutics Plc BCYC | $248 mln | $72,6 mln | 105,8% | −340,4% | — | — | 2,5% |
| Vanda Pharmaceuticals Inc. VNDA | $242 mln | $216 mln | 8,7% | −70,0% | — | — | 1,0% |
| Immuneering Corp IMRX | $241 mln | — | — | — | — | — | 2,1% |
| Lifecore Biomedical, Inc. De LFCR | $240 mln | $129 mln | 0,5% | −13,4% | −11,0% | — | 0,5% |
| Standard Biotools Inc. LAB | $237 mln | $85,3 mln | −6,2% | −129,2% | — | 2,8x | 4,7% |
| Greenwich LifeSciences, Inc. GLSI | $234 mln | — | — | — | — | — | 3,6% |
| BioAge Labs, Inc. BIOA | $229 mln | $9,0 mln | — | −1.031,5% | — | — | 7,8% |
| Mereo BioPharma Group plc MREO | $226 mln | $0,5 mln | — | −8.021,4% | — | — | 2,0% |
| Siga Technologies Inc SIGA | $224 mln | $94,6 mln | −31,8% | 25,1% | — | — | 1,0% |
| Keros Therapeutics, Inc. KROS | $223 mln | $244 mln | — | 27,7% | — | — | 0,6% |
| ADC Therapeutics SA ADCT | $223 mln | $81,4 mln | 14,9% | −149,3% | — | — | 10,0% |
| Natures Sunshine Products Inc NATR | $223 mln | $480 mln | 5,7% | 5,2% | — | 12,0x | 2,1% |
| Lyell Immunopharma, Inc. LYEL | $219 mln | $0,0 mln | −41,0% | −748.344,4% | — | — | 0,1% |
| BridgeBio Oncology Therapeutics, Inc. BBOT | $213 mln | — | — | — | — | — | 6,7% |
| GT Biopharma, Inc. GTBP | $212 mln | — | — | — | — | 1,3x | 1,1% |
| Korro Bio, Inc. KRRO | $211 mln | $6,4 mln | 181,5% | −1.906,4% | — | — | 0,6% |
| Galectin Therapeutics Inc GALT | $210 mln | — | — | — | — | — | 5,6% |
| Perspective Therapeutics, Inc. CATX | $194 mln | $0,9 mln | −39,2% | −12.846,6% | −140,4% | — | 28,8% |
| Camp4 Therapeutics Corp CAMP | $191 mln | $3,5 mln | 436,5% | −1.502,4% | — | — | 2,7% |
| Entrada Therapeutics, Inc. TRDA | $186 mln | $25,4 mln | −87,9% | −621,1% | — | — | 6,8% |
| Cartesian Therapeutics, Inc. RNAC | $185 mln | $2,8 mln | −92,8% | −5.127,1% | — | — | 3,6% |
| Evommune, Inc. EVMN | $184 mln | $13,0 mln | 85,7% | −623,6% | — | 0,9x | 2,1% |
| Minerva Neurosciences, Inc. NERV | $182 mln | — | — | — | — | — | 4,2% |
| Q32 Bio Inc. QTTB | $176 mln | $53,7 mln | — | 31,5% | — | 2,8x | 1,7% |
| Oramed Pharmaceuticals Inc. ORMP | $176 mln | $2,0 mln | — | −754,4% | — | 1,0x | 0,2% |
| PepGen Inc. PEPG | $174 mln | — | — | — | — | — | 6,7% |
| Sionna Therapeutics, Inc. SION | $163 mln | — | — | — | — | — | 5,3% |
| AN2 Therapeutics, Inc. ANTX | $159 mln | — | — | — | — | — | 2,5% |
| Alx Oncology Holdings Inc ALXO | $159 mln | — | — | — | — | — | 1,7% |
| Zentalis Pharmaceuticals, Inc. ZNTL | $158 mln | $0,0 mln | −100,0% | — | — | — | 8,3% |
| Akebia Therapeutics, Inc. AKBA | $153 mln | $236 mln | 47,5% | 9,9% | — | — | 0,8% |
| Upstream Bio, Inc. UPB | $150 mln | $2,9 mln | 20,4% | −5.618,8% | — | — | 8,4% |
| Macrogenics Inc MGNX | $143 mln | $150 mln | −0,3% | −48,7% | — | — | 38,0% |
| Foghorn Therapeutics Inc. FHTX | $141 mln | $30,9 mln | 36,8% | −279,5% | — | — | 0,5% |
| TuHURA Biosciences, Inc./NV HURA | $139 mln | $0,0 mln | — | — | — | — | 8,5% |
| Journey Medical Corp DERM | $138 mln | $61,9 mln | 10,2% | −13,2% | −19,5% | — | 1,4% |
| Medicus Pharma Ltd. MDCX | $138 mln | −$0,2 mln | −877,2% | 17.405,9% | — | — | 4,6% |
| Equillium, Inc. EQ | $138 mln | — | — | — | — | — | 3,1% |
| Nkarta, Inc. NKTX | $133 mln | $0,0 mln | — | — | — | — | 2,9% |
| Korsana Biosciences, Inc. KRSA | $133 mln | $2,1 mln | 3,7% | −239,8% | — | — | 6,3% |
| Curanex Pharmaceuticals Inc CURX | $132 mln | — | — | — | — | — | 10,8% |
| Organogenesis Holdings Inc. ORGO | $128 mln | $564 mln | 17,0% | 7,9% | — | — | 3,6% |
| Cumberland Pharmaceuticals Inc CPIX | $127 mln | $44,5 mln | 17,6% | −6,3% | −16,4% | — | 0,1% |
| OnKure Therapeutics, Inc. OKUR | $126 mln | $3,4 mln | — | −1.833,7% | — | — | 2,3% |
| Cue Biopharma, Inc. CUE | $118 mln | $27,5 mln | 195,7% | −96,7% | — | — | 1,2% |
| Scienture Holdings, Inc. SCNX | $114 mln | $0,4 mln | 216,0% | −9.868,1% | — | — | 4,0% |
| Rani Therapeutics Holdings, Inc. RANI | $113 mln | $1,6 mln | 58,9% | −2.346,0% | −210,3% | — | 3,1% |
| Spruce Biosciences, Inc. SPRB | $110 mln | $0,0 mln | −100,0% | — | — | — | 1,8% |
| Pyxis Oncology, Inc. PYXS | $108 mln | $13,9 mln | −14,2% | −609,2% | — | — | 1,8% |
| Unicycive Therapeutics, Inc. UNCY | $105 mln | — | — | — | — | — | 1,3% |
| Anixa Biosciences Inc ANIX | $102 mln | — | — | — | — | — | 7,6% |
| Rallybio Corp RLYB | $96,5 mln | $0,9 mln | 34,9% | −3.853,6% | — | 2,6x | 1,5% |
| Faeth Therapeutics, Inc. FTH | $96,4 mln | — | — | — | — | — | 15,0% |
| Coya Therapeutics, Inc. COYA | $92,4 mln | $7,9 mln | 123,6% | −283,9% | — | — | 4,8% |
| GENELUX Corp GNLX | $89,9 mln | $0,0 mln | 0,0% | −415.175,0% | — | — | 1,0% |
| Polaryx Therapeutics, Inc. PLYX | $89,3 mln | — | — | — | — | — | 4,6% |
| Tenax Therapeutics, Inc. TENX | $87,5 mln | $0,0 mln | — | — | — | — | 2,3% |
| Tonix Pharmaceuticals Holding Corp. TNXP | $86,0 mln | $13,1 mln | 29,8% | −959,1% | — | — | 0,8% |
| Neonc Technologies Holdings, Inc. NTHI | $80,7 mln | $0,0 mln | −51,8% | −145.601,0% | — | — | 10,8% |
| Corbus Pharmaceuticals Holdings, Inc. CRBP | $78,6 mln | — | — | — | — | — | 1,9% |
| Lexaria Bioscience Corp. LEXX | $76,4 mln | $0,7 mln | 52,0% | −1.683,1% | — | — | 3,0% |
| ProMIS Neurosciences Inc. PMN | $76,2 mln | — | — | — | — | — | 7,1% |
| Verrica Pharmaceuticals Inc. VRCA | $75,2 mln | $35,6 mln | 370,2% | −34,2% | — | — | 7,8% |
| iBio, Inc. IBIO | $74,7 mln | $0,1 mln | −75,0% | −35.141,0% | — | — | 8,4% |
| Lifevantage Corp LFVN | $74,4 mln | $183 mln | −20,1% | 3,3% | — | 14,7x | 2,0% |
| Inovio Pharmaceuticals, Inc. INO | $73,2 mln | $0,1 mln | −70,0% | −132.958,8% | — | — | 6,9% |
| Acrivon Therapeutics, Inc. ACRV | $72,4 mln | — | — | — | — | — | 1,7% |
| MAIA Biotechnology, Inc. MAIA | $69,9 mln | — | — | — | — | — | 1,8% |
| Medicinova Inc MNOV | $68,4 mln | $0,4 mln | — | −3.242,1% | — | — | 1,4% |
| PMV Pharmaceuticals, Inc. PMVP | $67,8 mln | $6,3 mln | −40,5% | −1.360,4% | — | — | 2,7% |
| Rafael Holdings, Inc. RFL | $67,1 mln | $0,9 mln | 44,0% | −3.179,8% | — | — | 2,3% |
| Cingulate Inc. CING | $65,7 mln | −$1,4 mln | −1.472,1% | 1.464,9% | — | — | 6,9% |
| Spero Therapeutics, Inc. SPRO | $64,3 mln | $66,8 mln | 39,2% | 9,5% | — | 7,9x | 1,8% |
| Citius Oncology, Inc. CTOR | $62,5 mln | — | — | — | — | — | 17,2% |
| PDS Biotechnology Corp PDSB | $61,8 mln | — | — | — | — | — | 4,3% |
| Fortress Biotech, Inc. FBIO | $61,4 mln | $63,3 mln | 9,7% | −111,0% | −222,0% | 0,7x | 3,0% |
| Skye Bioscience, Inc. SKYE | $61,1 mln | — | — | — | — | — | 4,9% |
| Oncolytics Biotech Inc ONCY | $60,1 mln | — | — | — | — | — | 0,4% |
| Telomir Pharmaceuticals, Inc. TELO | $59,3 mln | — | — | — | — | — | 3,5% |
| XBiotech Inc. XBIT | $58,8 mln | — | — | — | — | — | 2,0% |
| Heron Therapeutics, Inc. /De/ HRTX | $57,6 mln | $155 mln | 7,4% | −1,6% | — | — | 2,2% |
| OS Therapies Inc OSTX | $54,9 mln | — | — | — | — | — | 0,0% |
| Gain Therapeutics, Inc. GANX | $54,0 mln | — | — | — | — | — | 2,3% |
| Pliant Therapeutics, Inc. PLRX | $53,5 mln | $0,0 mln | — | — | — | — | 0,2% |
| Boundless Bio, Inc. BOLD | $53,0 mln | — | — | — | — | — | 3,3% |
| Nomad Power Solutions, Inc. NMAD | $51,3 mln | — | — | — | — | — | 5,8% |
| Longeveron Inc. LGVN | $50,2 mln | $1,2 mln | −49,9% | −1.942,2% | — | — | 0,6% |
| Connect Biopharma Holdings Ltd CNTB | $48,2 mln | $0,1 mln | −99,8% | −90.740,6% | — | — | 0,6% |
| Actinium Pharmaceuticals, Inc. ATNM | $47,7 mln | $0,1 mln | — | −40.274,4% | — | 4,3x | 5,0% |
| Werewolf Therapeutics, Inc. HOWL | $47,6 mln | — | — | — | — | — | 3,0% |
| Scynexis Inc SCYX | $44,8 mln | $20,6 mln | 449,9% | −78,0% | — | 3,0x | 0,7% |
| Biomea Fusion, Inc. BMEA | $43,4 mln | $1,9 mln | −67,1% | −4.494,7% | — | — | 2,6% |
| Adicet Bio, Inc. ACET | $42,9 mln | — | — | — | — | — | 6,8% |
| Lite Strategy, Inc. LITS | $40,1 mln | — | — | — | — | — | 2,5% |
| Aldeyra Therapeutics, Inc. ALDX | $39,2 mln | — | — | — | — | — | 0,7% |
| Rein Therapeutics, Inc. RNTX | $39,1 mln | $0,0 mln | — | — | — | — | 3,4% |
| Dogwood Therapeutics, Inc. DWTX | $38,2 mln | — | — | — | — | 0,4x | 0,0% |
| Annovis Bio, Inc. ANVS | $37,5 mln | $0,0 mln | — | — | — | — | 0,8% |
| Elicio Therapeutics, Inc. ELTX | $36,6 mln | — | — | — | — | — | 2,1% |
| CNS Pharmaceuticals, Inc. CNSP | $34,0 mln | — | — | — | — | — | 4,6% |
| Grace Therapeutics, Inc. GRCE | $33,3 mln | — | — | — | — | — | 0,8% |
| Incannex Healthcare Inc. IXHL | $30,8 mln | $0,0 mln | −100,0% | — | — | — | 1,5% |
| Filana Therapeutics, Inc. FLNA | $30,7 mln | — | — | — | — | — | 2,8% |
| Aardvark Therapeutics, Inc. AARD | $30,4 mln | $0,0 mln | — | — | — | — | 64,8% |
| Celularity Inc CELU | $28,7 mln | $26,6 mln | −51,0% | −230,9% | — | — | 6,9% |
| Nanoviricides, Inc. NNVC | $28,3 mln | $0,0 mln | — | — | — | — | 0,7% |
| Aprea Therapeutics, Inc. APRE | $27,7 mln | $0,3 mln | −81,0% | −4.630,4% | — | — | 4,4% |
| Rockwell Medical, Inc. RMTI | $27,5 mln | $69,3 mln | −31,8% | −6,8% | −17,8% | — | 1,7% |
| Abvc Biopharma, Inc. ABVC | $27,1 mln | $0,3 mln | −41,9% | −2.416,0% | −50,8% | — | 0,7% |
| Serina Therapeutics, Inc. SER | $27,0 mln | $0,1 mln | 132,1% | −18.478,5% | — | — | 6,3% |
| China Pharma Holdings, Inc. CPHI | $26,7 mln | $4,1 mln | −8,5% | −78,2% | −10,7% | — | 2,7% |
| NextCure, Inc. NXTC | $26,4 mln | — | — | — | — | — | 5,5% |
| BriaCell Therapeutics Corp. BCTX | $24,9 mln | — | — | — | — | 1,5x | 0,7% |
| Atossa Therapeutics, Inc. ATOS | $23,2 mln | — | — | — | — | — | 4,4% |
| Context Therapeutics Inc. CNTX | $22,8 mln | — | — | — | — | — | 1,6% |
| CalciMedica, Inc. CALC | $21,0 mln | $0,7 mln | −29,7% | −3.242,8% | — | — | 7,0% |
| TherapeuticsMD, Inc. TXMD | $21,0 mln | $3,0 mln | 71,6% | −145,3% | — | — | 2,7% |
| Seres Therapeutics, Inc. MCRB | $20,4 mln | $0,8 mln | — | −11.910,1% | — | — | 1,9% |
| Marker Therapeutics, Inc. MRKR | $18,5 mln | $3,5 mln | −46,2% | −363,4% | — | — | 10,3% |
| Kyntra Bio, Inc. KYNB | $18,5 mln | $6,4 mln | −78,3% | −712,7% | — | 0,1x | 12,3% |
| Adial Pharmaceuticals, Inc. ADIL | $18,1 mln | — | — | — | — | — | 7,1% |
| Quantum Cyber N.V. QUCY | $18,0 mln | $0,5 mln | −39,9% | −3.004,9% | −1.797,3% | — | 1,0% |
| Yarrow Bioscience, Inc. YARW | $16,5 mln | $0,6 mln | 13,8% | −5.219,1% | — | — | 1,7% |
| Neuphoria Therapeutics Inc. NEUP | $15,1 mln | $1,2 mln | −92,5% | −1.401,0% | — | — | 1,1% |
| Cellectar Biosciences, Inc. CLRB | $14,9 mln | — | — | — | — | — | 4,3% |
| Revelation Biosciences, Inc. REVB | $14,5 mln | — | — | — | — | 0,1x | 3,0% |
| Palatin Technologies Inc PTN | $14,4 mln | $8,8 mln | — | −98,2% | — | — | 7,3% |
| Kiora Pharmaceuticals Inc KPRX | $14,1 mln | $0,0 mln | −100,0% | — | — | — | 1,3% |
| Cocrystal Pharma, Inc. COCP | $13,1 mln | — | — | — | — | — | 4,2% |
| Pasithea Therapeutics Corp. KTTA | $13,0 mln | — | — | — | — | — | 9,1% |
| AEON Biopharma, Inc. AEON | $12,1 mln | — | — | — | — | — | 2,7% |
| Kairos Pharma, LTD. KAPA | $12,0 mln | — | — | — | — | — | 2,7% |
| Lipocine Inc. LPCN | $11,8 mln | $2,0 mln | −82,3% | −524,7% | — | — | 1,4% |
| Actuate Therapeutics, Inc. ACTU | $11,3 mln | — | — | — | — | — | 7,9% |
| Rocket One Inc. RKTO | $11,3 mln | — | — | — | — | — | 2,8% |
| Matinas BioPharma Holdings, Inc. MTNB | $10,9 mln | — | — | — | — | — | 0,5% |
| Bolt Biotherapeutics, Inc. BOLT | $10,6 mln | $7,7 mln | 0,1% | −469,3% | — | — | 49,6% |
| Citius Pharmaceuticals, Inc. CTXR | $10,6 mln | — | — | — | −8,4% | — | 8,8% |
| Biofrontera Inc. BFRI | $10,2 mln | $41,7 mln | 11,7% | −27,2% | — | — | 1,0% |
| Dare Bioscience, Inc. DARE | $9,6 mln | $1,0 mln | 10.412,2% | −1.315,5% | — | — | 0,9% |
| BullFrog AI Holdings, Inc. BFRG | $9,3 mln | $0,1 mln | — | −5.650,9% | — | — | 0,1% |
| Aspire-Lakewood Holdings, Inc. ASBP | $9,1 mln | $0,0 mln | — | −312.117,7% | — | 0,0x | 1,1% |
| Lisata Therapeutics, Inc. LSTA | $9,1 mln | $0,2 mln | −83,0% | −10.711,2% | — | — | 0,9% |
| Theriva Biologics, Inc. TOVX | $9,0 mln | — | — | — | −475,2% | 0,2x | 3,2% |
| Biovie Inc. BIVI | $9,0 mln | — | — | — | — | — | 3,1% |
| Tvardi Therapeutics, Inc. TVRD | $8,8 mln | — | — | — | — | 23,5x | 3,3% |
| MetaVia Inc. MTVA | $8,2 mln | $0,5 mln | −44,6% | −2.687,8% | — | — | 0,7% |
| Lantern Pharma Inc. LTRN | $7,9 mln | — | — | — | — | — | 0,8% |
| Tempest Therapeutics, Inc. TPST | $7,8 mln | — | — | — | — | — | 2,2% |
| Vistagen Therapeutics, Inc. VTGN | $7,7 mln | $1,3 mln | 161,1% | −5.683,7% | — | — | 3,9% |
| Artelo Biosciences, Inc. ARTL | $6,9 mln | — | — | — | — | 0,2x | 0,0% |
| Exicure, Inc. XCUR | $6,7 mln | $0,0 mln | −100,0% | — | — | — | 7,1% |
| Imunon, Inc. IMNN | $6,5 mln | — | — | — | — | — | 1,2% |
| Ensysce Biosciences, Inc. ENSC | $6,1 mln | $5,1 mln | −2,8% | −202,1% | — | — | 7,9% |
| InMed Pharmaceuticals Inc. INM | $6,0 mln | — | — | — | — | — | 8,3% |
| FibroBiologics, Inc. FBLG | $6,0 mln | — | — | — | — | 0,4x | 6,9% |
| Soligenix, Inc. SNGX | $5,8 mln | — | — | — | — | — | 0,1% |
| Enveric Biosciences, Inc. ENVB | $5,6 mln | −$0,0 mln | −150,0% | 8.774.400,0% | — | — | 4,1% |
| Alaunos Therapeutics, Inc. TCRT | $5,5 mln | $0,0 mln | −50,0% | −84.500,0% | — | — | 25,0% |
| Traws Pharma, Inc. TRAW | $5,4 mln | $2,8 mln | 1.134,5% | −640,7% | — | — | 6,6% |
| Pulmatrix, Inc. PULM | $5,4 mln | — | — | — | — | — | 4,2% |
| Alzamend Neuro, Inc. ALZN | $5,1 mln | — | — | — | — | — | 0,9% |
| Processa Pharmaceuticals, Inc. PCSA | $5,0 mln | — | — | — | — | 1,8x | 2,7% |
| Apimeds Pharmaceuticals US, Inc. APUS | $5,0 mln | — | — | — | — | — | 8,5% |
| Shuttle Pharmaceuticals Holdings, Inc. SHPH | $4,9 mln | — | — | — | — | 0,2x | 5,4% |
| Acurx Pharmaceuticals, Inc. ACXP | $4,8 mln | — | — | — | — | — | 0,4% |
| Xenetic Biosciences, Inc. XBIO | $3,9 mln | $3,0 mln | 19,0% | −95,2% | — | — | 10,9% |
| Vyome Holdings, Inc HIND | $3,9 mln | $0,3 mln | 24,4% | −3.269,5% | — | 0,0x | 0,6% |
| Dermata Therapeutics, Inc. DRMA | $3,1 mln | — | — | — | — | — | 9,6% |
| Cadrenal Therapeutics, Inc. CVKD | $2,8 mln | — | — | — | — | — | 1,0% |
| GRI Bio, Inc. GRI | $2,6 mln | — | — | — | — | 0,0x | 2,1% |
| Mustang Bio, Inc. MBIO | $2,5 mln | — | — | — | — | — | 0,2% |
| Ernexa Therapeutics Inc. ERNA | $2,4 mln | — | — | — | — | 0,0x | 0,5% |
| 60 Degrees Pharmaceuticals, Inc. SXTP | $2,3 mln | $1,0 mln | 65,5% | −771,6% | −710,7% | — | 0,7% |
| Aptevo Therapeutics Inc. APVO | $1,9 mln | — | — | — | — | 0,0x | 0,0% |
| Oragenics Inc OGEN | $1,8 mln | — | — | — | — | 0,4x | 2,9% |
| Transcode Therapeutics, Inc. RNAZ | $1,7 mln | — | — | — | — | — | 3,2% |
| Jupiter Neurosciences, Inc. JUNS | $1,7 mln | $0,0 mln | — | −40.865,6% | — | 4,0x | 15,5% |
| Jaguar Health, Inc. JAGX | $1,7 mln | $11,5 mln | −1,5% | −398,8% | — | 0,0x | 5,1% |
| Nuvation Bio Inc. NUVB | $1,6 mln | $62,9 mln | 699,0% | −338,7% | — | — | 2,8% |
| HCW Biologics Inc. HCWB | $1,6 mln | $0,1 mln | −97,9% | −24.285,1% | −136,4% | 0,0x | 4,5% |
| Azitra, Inc. AZTR | $1,4 mln | $0,0 mln | −100,0% | — | — | 1,2x | 0,0% |
| Silo Pharma, Inc. SILO | $1,3 mln | $0,1 mln | 0,0% | −5.937,2% | — | 0,7x | 0,0% |
| Lunai Bioworks Inc. LNAI | $1,0 mln | $0,1 mln | — | −16.726,7% | — | — | 37,3% |
| Onconetix, Inc. ONCO | $0,9 mln | $0,8 mln | −67,7% | −2.190,0% | — | 0,0x | 2,8% |
| Geron Corp GERN | $0,8 mln | — | — | — | −20,2% | — | 0,9% |
| Decoy Therapeutics Inc. DCOY | $0,5 mln | — | — | — | — | 0,0x | 5,8% |
| Nexentis Technologies Inc. NXTS | $0,4 mln | $0,0 mln | −100,0% | — | −26,4% | 0,0x | 7,5% |
| Propanc Biopharma, Inc. PPCB | $0,3 mln | — | — | — | — | — | 2,2% |
| CDT Equity Inc. CDT | $0,1 mln | — | — | — | — | 0,0x | 0,1% |
| Karyopharm Therapeutics Inc. KPTI | $0,0 mln | $146 mln | 0,6% | −62,1% | — | — | 5,2% |
| KALA BIO, Inc. KALA | $0,0 mln | $0,0 mln | — | — | — | 0,0x | 2,5% |
| Spyre Therapeutics, Inc. SYRE | — | $0,0 mln | — | — | — | — | 2,2% |
| Viridian Therapeutics, Inc.\DE VRDN | — | $70,8 mln | 23.359,9% | −512,9% | — | — | 2,0% |
| UroGen Pharma Ltd. URGN | — | $110 mln | 21,4% | −113,7% | — | — | 1,9% |
| Evotec SE EVO | — | $889 mln | 3,1% | −7,1% | −6,3% | — | �� |
| Bright Minds Biosciences Inc. DRUG | — | — | — | — | — | — | �� |
| Eupraxia Pharmaceuticals Inc. EPRX | — | $0,0 mln | — | — | — | — | �� |
| Crescent Biopharma, Inc. CBIO | — | $10,8 mln | — | −1.407,5% | — | — | 2,4% |
| Ovid Therapeutics Inc. OVID | — | $7,3 mln | 1.181,3% | −585,2% | — | — | 8,9% |
| Oculis Holding AG OCS | — | $1,4 mln | 85,2% | −6.811,8% | — | — | �� |
| Monopar Therapeutics MNPR | — | $0,0 mln | — | — | — | — | 2,7% |
| DiaMedica Therapeutics Inc. DMAC | — | — | — | — | — | — | 1,0% |
| Kamada Ltd KMDA | — | $180 mln | 12,1% | 14,5% | 11,1% | — | �� |
| Prenetics Global Ltd PRE | — | $92,4 mln | 479,8% | −48,1% | — | — | �� |
| Larimar Therapeutics, Inc. LRMR | — | — | — | — | — | — | 3,5% |
| AC Immune SA ACIU | — | $4,3 mln | −86,1% | −1.940,0% | — | — | �� |
| InflaRx N.V. IFRX | — | $0,0 mln | −81,5% | — | — | — | �� |
| Sol-Gel Technologies Ltd. SLGL | — | $19,4 mln | 68,0% | −38,9% | — | — | �� |
| ProQR Therapeutics N.V. PRQR | — | $17,9 mln | −12,3% | −273,1% | — | — | �� |
| Adagene Inc. ADAG | — | $7,7 mln | 7.333,0% | −279,5% | — | — | �� |
| Nervgen Pharma Corp. NGEN | — | — | — | — | — | — | �� |
| NovaBridge Biosciences NBP | — | — | — | — | — | — | �� |
| Jyong Biotech Ltd. MENS | — | — | — | — | — | — | �� |
| Satellos Bioscience Inc. MSLE | — | — | — | — | — | — | �� |
| Organigram Global Inc. OGI | — | $185 mln | — | −5,9% | −4,5% | — | �� |
| Tiziana Life Sciences Ltd TLSA | — | — | — | — | — | — | �� |
| NRX Pharmaceuticals, Inc. NRXP | — | $1,2 mln | — | −1.324,4% | — | — | 3,8% |
| vTv Therapeutics Inc. VTVT | — | $0,0 mln | −100,0% | — | — | — | 5,9% |
| BGM Group Ltd. BGM | — | $37,9 mln | 51,1% | −33,2% | — | — | �� |
| Kazia Therapeutics Ltd KZIA | — | $0,0 mln | −98,2% | — | — | — | �� |
| Milestone Pharmaceuticals Inc. MIST | — | — | — | — | — | — | 7,8% |
| Zhengye Biotechnology Holding Ltd ZYBT | — | $16,2 mln | −37,5% | −60,6% | −19,9% | — | �� |
| Intercure Ltd. INCR | — | $78,3 mln | 21,3% | −10,1% | −4,0% | — | �� |
| Apollomics Inc. APLM | — | $8,5 mln | — | — | — | — | �� |
| MindWalk Holdings Corp. HYFT | — | $11,3 mln | 47,9% | — | — | — | �� |
| Xilio Therapeutics, Inc. XLO | — | $43,8 mln | 589,9% | −95,9% | — | — | 5,7% |
| Talphera, Inc. TLPH | — | $0,0 mln | — | −48.157,1% | — | — | 2,9% |
| Clene Inc. CLNN | — | $0,2 mln | −41,5% | −11.541,5% | — | — | 0,0% |
| Alterity Therapeutics Ltd ATHE | — | $1,2 mln | −77,8% | — | — | — | �� |
| Veru Inc. VERU | — | — | — | — | — | — | 2,2% |
| Nasus Pharma Ltd NSRX | — | $1,2 mld | — | −0,4% | — | — | �� |
| Edesa Biotech, Inc. EDSA | — | — | — | — | — | — | 0,4% |
| Bioharvest Sciences Inc. BHST | — | $34,5 mln | 37,0% | −16,2% | −171,2% | — | �� |
| CervoMed Inc. CRVO | — | $4,0 mln | −58,9% | −706,2% | — | — | 3,1% |
| Impact Biomedical Inc. IBO | — | $0,0 mln | — | −13.381,3% | — | 4,1x | 5,3% |
| Mira Pharmaceuticals, Inc. MIRA | — | $0,1 mln | −40,3% | — | — | — | 1,5% |
| IMMUTEP Ltd IMMP | — | $16,4 mln | 144,9% | — | — | — | �� |
| Aytu Biopharma, Inc AYTU | — | $57,6 mln | −13,3% | −14,4% | −33,0% | — | 4,0% |
| BeyondSpring Inc. BYSI | — | $0,0 mln | — | — | — | — | 3,1% |
| Universe Pharmaceuticals INC UPC | — | $17,9 mld | −22,4% | −16,3% | −7,2% | — | �� |
| Quoin Pharmaceuticals Ltd. QNRX | — | — | — | — | — | — | 0,2% |
| NewcelX Ltd. NCEL | — | — | — | — | −37,5% | — | �� |
| Radiopharm Theranostics Ltd RADX | — | $2,8 mln | −23,8% | −2.051,5% | — | — | �� |
| Allarity Therapeutics, Inc. ALLR | — | $0,3 mln | — | −3.939,1% | — | — | 2,2% |
| Phio Pharmaceuticals Corp. PHIO | — | — | — | — | — | — | 2,3% |
| BioLineRx Ltd. BLRX | — | $1,2 mln | −95,9% | −871,8% | — | — | �� |
| Moleculin Biotech, Inc. MBRX | — | $0,0 mln | — | — | — | — | 10,4% |
| Sunshine Biopharma Inc. SBFM | — | $36,3 mln | 4,1% | −17,2% | — | — | 10,2% |
| GeoVax Labs, Inc. GOVX | — | $2,5 mln | −37,1% | −869,4% | — | — | 3,2% |
| PMGC Holdings Inc. ELAB | — | $0,6 mln | — | — | — | — | 1,7% |
| Valion Bio, Inc. VBIO | — | — | — | — | — | — | 1,7% |
| Genprex, Inc. GNPX | — | — | — | — | — | — | 8,6% |
Biological Products, (No Diagnostic Substances) · 136
| Bedrijf | Beurswaarde | Omzet | Groei | Oper. marge | ROIC | K/W | Dag |
|---|---|---|---|---|---|---|---|
| Anavex Life Sciences Corp. AVXL | $123,6 mld | $4,7 mln | −36,1% | −1.098,9% | — | — | 2,2% |
| Revolution Medicines, Inc. RVMD | $39,4 mld | $0,0 mln | — | — | — | — | 0,4% |
| Kymera Therapeutics, Inc. KYMR | $10,9 mld | $39,2 mln | −16,7% | −891,1% | — | — | 0,1% |
| Vaxcyte, Inc. PCVX | $8,7 mld | — | — | — | — | — | 3,9% |
| Twist Bioscience Corp TWST | $8,7 mld | $377 mln | 20,3% | −36,2% | — | — | 3,3% |
| ImmunityBio, Inc. IBRX | $8,6 mld | $113 mln | 668,3% | −226,0% | — | — | 1,1% |
| Immunovant, Inc. IMVT | $5,8 mld | — | — | — | — | — | 2,4% |
| Kodiak Sciences Inc. KOD | $5,5 mld | — | — | — | — | — | 2,2% |
| CG Oncology, Inc. CGON | $5,4 mld | $4,0 mln | 254,7% | −4.722,1% | −1.120,8% | — | 1,3% |
| Scholar Rock Holding Corp SRRK | $5,4 mld | $0,0 mln | — | — | — | — | 1,1% |
| CRISPR Therapeutics AG CRSP | $4,8 mld | $3,5 mln | −90,6% | −18.933,6% | — | — | 1,2% |
| DBV Technologies S.A. DBVT | $4,2 mld | $5,6 mln | 35,8% | −2.609,2% | — | — | 0,7% |
| Adaptive Biotechnologies Corp ADPT | $4,1 mld | $277 mln | 54,8% | −20,6% | −36,7% | — | 4,5% |
| Denali Therapeutics Inc. DNLI | $3,4 mld | $0,0 mln | — | — | — | — | 1,3% |
| Tarsus Pharmaceuticals, Inc. TARS | $3,0 mld | $451 mln | 146,7% | −15,7% | — | — | 5,4% |
| Beam Therapeutics Inc. BEAM | $2,5 mld | $140 mln | 120,0% | −274,6% | — | — | 2,1% |
| Vericel Corp VCEL | $2,2 mld | $276 mln | 16,5% | 4,0% | — | 88,6x | 1,0% |
| Biocryst Pharmaceuticals Inc BCRX | $2,0 mld | $875 mln | 94,1% | 39,0% | — | — | 1,7% |
| Recursion Pharmaceuticals, Inc. RXRX | $2,0 mld | $74,7 mln | 26,9% | −867,9% | −126,0% | — | 3,4% |
| Maze Therapeutics, Inc. MAZE | $1,8 mld | — | — | — | — | — | 2,9% |
| Vir Biotechnology, Inc. VIR | $1,8 mld | $68,6 mln | −7,6% | −699,2% | — | — | 1,3% |
| Novavax Inc NVAX | $1,6 mld | $1,1 mld | 64,7% | 40,3% | — | — | 2,9% |
| Mesoblast Ltd MESO | $1,6 mld | $120 mln | 599,2% | — | — | — | 2,2% |
| Immunocore Holdings plc IMCR | $1,6 mld | $400 mln | 29,0% | −11,3% | — | — | 3,5% |
| Inhibrx Biosciences, Inc. INBX | $1,5 mld | $1,3 mln | 550,0% | −10.386,5% | — | — | 3,8% |
| Taysha Gene Therapies, Inc. TSHA | $1,5 mld | $9,8 mln | 17,3% | −1.130,6% | — | — | 1,1% |
| Alvotech ALVO | $1,3 mld | $586 mln | 19,7% | 13,3% | 6,0% | 45,8x | 4,4% |
| Replimune Group, Inc. REPL | $1,1 mld | — | — | — | — | — | 4,4% |
| Monte Rosa Therapeutics, Inc. GLUE | $1,1 mld | $124 mln | 63,5% | −43,8% | — | — | 2,4% |
| Vor Biopharma Inc. VOR | $992 mln | — | — | — | — | 0,1x | 3,6% |
| Immatics N.V. IMTX | $894 mln | — | — | — | — | — | 3,1% |
| MeiraGTx Holdings plc MGTX | $864 mln | $81,4 mln | 144,6% | −130,2% | — | 13,0x | 5,7% |
| Solid Biosciences Inc. SLDB | $851 mln | — | — | — | — | — | 4,4% |
| 4D Molecular Therapeutics, Inc. FDMT | $759 mln | $85,2 mln | 230.194,6% | −187,2% | −122,4% | — | 8,9% |
| Greenland Mines Ltd GRML | $731 mln | — | — | — | — | — | 3,3% |
| Sana Biotechnology, Inc. SANA | $689 mln | — | — | — | — | — | 1,7% |
| Prime Medicine, Inc. PRME | $650 mln | $4,6 mln | 55,3% | −4.498,1% | — | — | 1,6% |
| Aura Biosciences, Inc. AURA | $598 mln | $6,6 mln | −29,7% | −1.701,0% | — | — | 2,5% |
| Candel Therapeutics, Inc. CADL | $595 mln | — | — | — | — | — | 4,2% |
| Surrozen, Inc./DE SRZN | $590 mln | $3,5 mln | −67,4% | −1.210,6% | — | — | 1,0% |
| Ginkgo Bioworks Holdings, Inc. DNA | $554 mln | $170 mln | −25,1% | −185,3% | — | — | 2,9% |
| Zura Bio Ltd ZURA | $426 mln | — | — | — | — | — | 4,8% |
| Allogene Therapeutics, Inc. ALLO | $411 mln | $0,0 mln | −100,0% | — | — | — | 0,0% |
| Autolus Therapeutics plc AUTL | $410 mln | $75,4 mln | 644,9% | −358,9% | — | — | 2,5% |
| X4 Pharmaceuticals, Inc XFOR | $409 mln | $6,5 mln | 150,0% | −1.336,7% | −155,1% | 2,6x | 1,3% |
| C4 Therapeutics, Inc. CCCC | $400 mln | $35,9 mln | 1,0% | −320,5% | — | — | 3,8% |
| Tectonic Therapeutic, Inc. TECX | $381 mln | — | — | — | — | — | 4,8% |
| Fennec Pharmaceuticals Inc. FENC | $367 mln | $44,6 mln | −6,1% | −14,1% | — | — | 2,3% |
| REGENXBIO Inc. RGNX | $354 mln | $170 mln | 104,5% | −94,6% | — | — | 6,8% |
| Kyverna Therapeutics, Inc. KYTX | $328 mln | — | — | — | — | — | 5,9% |
| Century Therapeutics, Inc. IPSC | $300 mln | $109 mln | 1.556,8% | −15,8% | — | — | 7,6% |
| Editas Medicine, Inc. EDIT | $286 mln | $40,5 mln | 25,4% | −394,9% | — | — | 3,6% |
| Palisade Bio, Inc. PALI | $281 mln | $0,0 mln | — | — | — | 2,0x | 1,5% |
| Inhibikase Therapeutics, Inc. IKT | $278 mln | $3,7 mln | — | −1.399,0% | — | — | 2,5% |
| Agenus Inc AGEN | $262 mln | $114 mln | 10,4% | −17,7% | — | 2,1x | 2,8% |
| Lineage Cell Therapeutics, Inc. LCTX | $261 mln | $14,6 mln | 53,2% | −251,6% | — | — | 1,5% |
| Fate Therapeutics Inc FATE | $254 mln | $6,6 mln | −51,2% | −2.222,4% | — | — | 1,0% |
| Ocugen, Inc. OCGN | $251 mln | $4,4 mln | 8,8% | −1.425,7% | — | — | 6,4% |
| Artiva Biotherapeutics, Inc. ARTV | $242 mln | $0,0 mln | −100,0% | — | — | — | 0,8% |
| Lexeo Therapeutics, Inc. LXEO | $240 mln | — | — | — | — | — | 3,1% |
| SAB Biotherapeutics, Inc. SABS | $226 mln | $0,0 mln | −100,0% | — | — | 12,3x | 6,6% |
| Armata Pharmaceuticals, Inc. ARMP | $226 mln | $4,9 mln | −5,2% | −747,0% | — | — | 5,5% |
| Cabaletta Bio, Inc. CABA | $222 mln | — | — | — | — | — | 3,3% |
| Protalix BioTherapeutics, Inc. PLX | $211 mln | $52,7 mln | −1,2% | −10,4% | — | 10,6x | 0,8% |
| Alector, Inc. ALEC | $204 mln | $21,0 mln | −79,1% | −741,3% | — | — | 0,0% |
| IRulya Therapeutics Inc. IRLA | $203 mln | — | — | — | — | 0,5x | 0,8% |
| Invivyd, Inc. IVVD | $197 mln | $53,4 mln | 110,5% | −104,0% | — | — | 0,5% |
| Alpha Cognition Inc. ACOG | $182 mln | $10,2 mln | — | −221,7% | — | — | 0,4% |
| Precision Biosciences Inc DTIL | $172 mln | $34,3 mln | −50,1% | −152,2% | — | — | 2,1% |
| Coherus Oncology, Inc. CHRS | $156 mln | $42,2 mln | 59,8% | −429,5% | — | — | 3,8% |
| Sutro Biopharma, Inc. STRO | $155 mln | $102 mln | 65,2% | −154,5% | — | — | 9,3% |
| Entera Bio Ltd. ENTX | $147 mln | $0,0 mln | −76,8% | −27.450,0% | — | 8,6x | 3,3% |
| Acumen Pharmaceuticals, Inc. ABOS | $143 mln | — | — | — | — | — | 3,9% |
| Liminatus Pharma, Inc. LIMN | $142 mln | — | — | — | — | — | 5,5% |
| Protara Therapeutics, Inc. TARA | $142 mln | — | — | — | — | — | 4,5% |
| Atara Biotherapeutics, Inc. ATRA | $129 mln | $121 mln | −6,3% | 29,7% | — | — | 8,9% |
| LeonaBio, Inc. LONA | $115 mln | — | — | — | — | — | 2,6% |
| enGene Therapeutics Inc. ENGN | $109 mln | — | — | — | — | 0,6x | 1,3% |
| Black Diamond Therapeutics, Inc. BDTX | $108 mln | $70,0 mln | — | 17,9% | — | — | 9,6% |
| Voyager Therapeutics, Inc. VYGR | $105 mln | $40,4 mln | −49,5% | −326,6% | — | — | 6,5% |
| Humacyte, Inc. HUMA | $102 mln | $2,0 mln | — | −5.306,0% | — | — | 5,4% |
| LENZ Therapeutics, Inc. LENZ | $99,1 mln | $19,1 mln | — | −477,5% | — | — | 2,8% |
| Eloxx Pharmaceuticals, Inc. ELOX | $86,9 mln | $0,0 mln | −100,0% | — | — | — | 2,4% |
| Tenaya Therapeutics, Inc. TNYA | $84,6 mln | — | — | — | — | — | 0,3% |
| Outlook Therapeutics, Inc. OTLK | $71,0 mln | $1,4 mln | — | −4.744,4% | — | — | 7,8% |
| Neumora Therapeutics, Inc. NMRA | $70,3 mln | — | — | — | — | — | 6,5% |
| ImageneBio, Inc. IMA | $68,2 mln | $0,8 mln | −77,1% | −6.056,4% | — | — | 4,3% |
| Champions Oncology, Inc. CSBR | $65,3 mln | $59,4 mln | 4,4% | −1,9% | — | — | 0,8% |
| Cognition Therapeutics Inc CGTX | $65,1 mln | — | — | — | — | — | 2,6% |
| Cardiff Oncology, Inc. CRDF | $62,1 mln | $0,6 mln | −13,2% | −8.256,3% | — | — | 2,2% |
| Pelthos Therapeutics Inc. PTHS | $60,2 mln | $16,8 mln | — | −193,1% | — | — | 13,2% |
| Caribou Biosciences, Inc. CRBU | $53,8 mln | $11,2 mln | 11,7% | −1.329,4% | — | — | 4,9% |
| MiNK Therapeutics, Inc. INKT | $53,8 mln | $0,2 mln | 4,4% | −7.015,6% | — | — | 6,5% |
| Aligos Therapeutics, Inc. ALGS | $49,9 mln | $2,2 mln | −39,5% | −4.024,9% | — | — | 0,8% |
| Kalaris Therapeutics, Inc. KLRS | $44,5 mln | — | — | — | — | — | 6,0% |
| Instil Bio, Inc. TIL | $39,6 mln | — | — | — | — | — | 2,5% |
| Inmune Bio, Inc. INMB | $39,0 mln | $0,1 mln | 257,1% | −94.766,0% | — | — | 5,2% |
| Elutia Inc. ELUT | $37,0 mln | $12,3 mln | −15,0% | −218,9% | — | 0,8x | 2,8% |
| Exozymes Inc. EXOZ | $34,6 mln | — | — | — | — | — | 2,6% |
| Metagenomi Therapeutics, Inc. MGX | $30,3 mln | $25,2 mln | −51,8% | −380,9% | — | — | 1,3% |
| TScan Therapeutics, Inc. TCRX | $26,4 mln | $10,3 mln | 266,7% | −1.315,4% | −3.300,3% | — | 6,0% |
| Tevogen Inc. TVGN | $25,0 mln | −$0,2 mln | — | 13.364,3% | — | — | 4,1% |
| In8Bio, Inc. INAB | $20,4 mln | — | — | — | — | — | 6,5% |
| Cel Sci Corp CVM | $19,9 mln | −$0,6 mln | — | 3.823,3% | −151,2% | — | 1,9% |
| Scilex Holding Co SCLX | $16,2 mln | $30,3 mln | −46,5% | −1.143,7% | — | — | 4,9% |
| aTYR PHARMA INC ATYR | $16,2 mln | $0,2 mln | −19,1% | −40.856,3% | — | — | 2,9% |
| Jasper Therapeutics, Inc. JSPR | $14,6 mln | — | — | — | — | — | 2,9% |
| Dyadic International Inc DYAI | $14,5 mln | $3,1 mln | −11,6% | −232,8% | — | — | 0,7% |
| Passage BIO, Inc. PASG | $10,8 mln | — | — | — | — | — | 4,0% |
| Pluri Inc. PLUR | $9,6 mln | $1,0 mln | −24,0% | −2.454,5% | — | — | 2,0% |
| Intensity Therapeutics, Inc. INTS | $8,8 mln | — | — | — | — | — | 1,9% |
| Iovance Biotherapeutics, Inc. IOVA | $6,3 mln | $264 mln | 60,6% | −153,1% | — | — | 0,4% |
| Senti Biosciences Holdings, Inc. SNTI | $5,9 mln | $0,0 mln | — | −312.631,8% | — | — | 1,1% |
| PharmaCyte Biotech, Inc. PMCB | $3,8 mln | $0,0 mln | — | — | — | — | 1,5% |
| Creative Medical Technology Holdings, Inc. CELZ | $2,7 mln | $0,0 mln | −45,5% | −102.380,0% | — | — | 4,4% |
| AIM ImmunoTech Inc. AIM | $2,7 mln | $0,1 mln | −48,2% | −13.254,5% | — | — | 2,9% |
| Calidi Biotherapeutics, Inc. CLDI | $0,9 mln | — | — | — | — | 0,0x | 0,8% |
| Curis Inc CRIS | $0,8 mln | $9,4 mln | −13,4% | −60,5% | −1.125,5% | 0,0x | 4,6% |
| VivoSim Labs, INC. VIVS | $0,8 mln | $0,1 mln | −9,0% | −8.768,7% | — | — | 6,8% |
| Silexion Therapeutics Corp SLXN | $0,1 mln | — | — | — | — | — | 14,3% |
| Cullinan Therapeutics, Inc. CGEM | — | — | — | — | — | — | 3,7% |
| Prokidney Corp. PROK | — | $0,9 mln | 1.075,0% | −18.477,8% | — | — | 1,4% |
| Valneva SE VALN | — | $197 mln | 7,4% | −47,0% | −35,4% | — | �� |
| AgomAb Therapeutics NV AGMB | — | — | — | — | — | — | �� |
| Compugen Ltd CGEN | — | $72,8 mln | 161,1% | 43,1% | — | — | �� |
| Innate Pharma SA IPHA | — | $10,2 mln | −53,3% | −599,8% | — | — | �� |
| Compass Therapeutics, Inc. CMPX | — | $0,0 mln | −100,0% | — | — | — | 5,1% |
| Cardiol Therapeutics Inc. CRDL | — | — | — | — | — | — | �� |
| Molecular Partners Ag MOLN | — | $0,0 mln | −100,0% | — | — | — | �� |
| Cellectis S.A. CLLS | — | $72,9 mln | 75,8% | −45,3% | — | — | �� |
| OKYO Pharma Ltd OKYO | — | — | — | — | — | — | �� |
| Evaxion A/S EVAX | — | $7,5 mln | 125,1% | −122,7% | — | — | �� |
| Genenta Science S.p.A. GNTA | — | — | — | — | — | — | �� |
| Black Hawk Acquisition Corp BKHA | — | $2,3 mln | −9,1% | −40,5% | — | — | 25,9% |
| BioCardia, Inc. BCDA | — | $0,0 mln | −100,0% | — | — | — | 0,8% |
| Relay Therapeutics, Inc. RLAY | — | $15,4 mln | 53,4% | −1.971,6% | — | — | 0,9% |
Surgical & Medical Instruments & Apparatus · 97
| Bedrijf | Beurswaarde | Omzet | Groei | Oper. marge | ROIC | K/W | Dag |
|---|---|---|---|---|---|---|---|
| Medline Inc. MDLN | $29,3 mld | $28,4 mld | 11,5% | 7,8% | 9,6% | — | 2,3% |
| Teleflex Inc TFX | $6,0 mld | $2,0 mld | 17,2% | 5,9% | 2,2% | — | 0,2% |
| Merit Medical Systems Inc MMSI | $5,6 mld | $1,5 mld | 11,8% | 12,2% | 7,4% | 38,4x | 0,7% |
| MiniMed Group, Inc. MMED | $5,2 mld | $3,1 mld | 14,3% | −6,1% | — | — | 0,3% |
| Heartflow, Inc. HTFL | $4,9 mld | $176 mln | 39,9% | −36,4% | — | 18,7x | 2,3% |
| iRhythm Holdings, Inc. IRTC | $4,0 mld | $747 mln | 26,2% | −7,7% | — | — | 1,4% |
| AtriCure, Inc. ATRC | $2,9 mld | $535 mln | 14,9% | −1,8% | −1,9% | — | 0,6% |
| Ufp Technologies Inc UFPT | $2,3 mld | $603 mln | 19,5% | 15,3% | 14,2% | 31,9x | 0,5% |
| Alphatec Holdings, Inc. ATEC | $1,7 mld | $764 mln | 25,0% | −10,7% | −13,5% | — | 2,2% |
| NovoCure Ltd NVCR | $1,7 mld | $655 mln | 8,3% | −23,5% | −27,5% | — | 2,8% |
| Kestra Medical Technologies, Ltd. KMTS | $1,7 mld | $95,1 mln | 59,0% | −141,6% | −100,5% | — | 1,6% |
| SkinHealth Systems Inc. SKIN | $1,4 mld | $301 mln | −10,0% | −6,9% | — | — | 1,9% |
| Tandem Diabetes Care Inc TNDM | $1,2 mld | $1,0 mld | 7,9% | −18,5% | −85,7% | — | 1,6% |
| PROCEPT BioRobotics Corp PRCT | $1,1 mld | $308 mln | 37,2% | −33,7% | −62,6% | — | 0,3% |
| Iradimed Corp IRMD | $1,1 mld | $83,8 mln | 14,4% | 31,2% | — | 47,9x | 2,1% |
| Alpha Tau Medical Ltd. DRTS | $1,1 mld | — | — | — | — | — | 2,0% |
| Bioventus Inc. BVS | $1,1 mld | $568 mln | −0,9% | 9,5% | 12,6% | 19,4x | 0,5% |
| SI-BONE, Inc. SIBN | $955 mln | $201 mln | 20,2% | −11,1% | −10,3% | — | 0,4% |
| SpyGlass Pharma, Inc. SGP | $952 mln | — | — | — | — | — | 0,9% |
| Beta Bionics, Inc. BBNX | $853 mln | $100 mln | 53,9% | −71,5% | — | — | 0,9% |
| Orthopediatrics Corp KIDS | $589 mln | $236 mln | 15,4% | −16,6% | −7,9% | — | 0,8% |
| Mimedx Group, Inc. MDXG | $578 mln | $419 mln | 20,0% | 15,3% | 43,2% | 97,8x | 0,5% |
| Delcath Systems, Inc. DCTH | $573 mln | $85,2 mln | 129,1% | 0,8% | — | — | 2,2% |
| Tactile Systems Technology Inc TCMD | $545 mln | $330 mln | 12,5% | 8,9% | 14,0% | 22,1x | 0,4% |
| Angiodynamics Inc ANGO | $520 mln | $320 mln | 9,5% | −12,5% | — | — | 2,9% |
| Sight Sciences, Inc. SGHT | $490 mln | $77,4 mln | −3,1% | −48,0% | −204,1% | — | 1,1% |
| AVITA Medical, Inc. RCEL | $477 mln | $71,6 mln | 11,5% | −59,4% | −412,3% | — | 0,6% |
| SS Innovations International, Inc. SSII | $471 mln | $42,5 mln | 105,7% | −19,3% | — | — | 5,1% |
| Cerus Corp CERS | $467 mln | $234 mln | 16,1% | −3,7% | — | — | 0,9% |
| NeuroPace Inc NPCE | $440 mln | $100,0 mln | 25,1% | −16,3% | −76,6% | — | 1,8% |
| Shoulder Innovations, Inc. SI | $408 mln | $47,3 mln | 49,6% | −55,6% | −66,3% | 0,1x | 0,5% |
| Orthofix Medical Inc. OFIX | $401 mln | $822 mln | 2,9% | −9,9% | −12,2% | — | 1,8% |
| Carlsmed, Inc. CARL | $395 mln | $50,5 mln | 85,9% | −60,5% | −546,2% | 132,1x | 0,5% |
| Embecta Corp. EMBC | $393 mln | $1,1 mld | −3,8% | 22,4% | 32,5% | 4,6x | 2,2% |
| Orchestra BioMed Holdings, Inc. OBIO | $357 mln | $33,5 mln | 1.169,2% | −154,7% | — | — | 2,2% |
| Cytosorbents Corp CTSO | $331 mln | $37,1 mln | 4,1% | −39,8% | −71,4% | — | 12,3% |
| Anika Therapeutics, Inc. ANIK | $294 mln | $113 mln | −5,9% | −9,8% | — | — | 1,6% |
| InfuSystem Holdings, Inc INFU | $292 mln | $143 mln | 6,4% | 8,3% | 10,5% | 34,9x | 1,4% |
| Orasure Technologies Inc OSUR | $290 mln | $115 mln | −38,1% | −62,6% | — | — | 8,7% |
| Treace Medical Concepts, Inc. TMCI | $278 mln | $213 mln | 1,6% | −25,5% | −44,4% | — | 0,2% |
| ClearPoint Neuro, Inc. CLPT | $276 mln | $37,0 mln | 17,8% | −65,4% | −61,2% | — | 1,2% |
| Utah Medical Products Inc UTMD | $236 mln | $38,5 mln | −5,8% | 29,6% | 27,2% | 22,6x | 1,1% |
| TriSalus Life Sciences, Inc. TLSI | $209 mln | $45,2 mln | 53,4% | −59,7% | — | — | 1,9% |
| Pro Dex Inc PDEX | $206 mln | $77,5 mln | 16,5% | 16,8% | 17,7% | 15,1x | 0,3% |
| Profound Medical Corp. PROF | $202 mln | $16,1 mln | 50,7% | −256,3% | −290,7% | 3,7x | 3,5% |
| Fractyl Health, Inc. GUTS | $171 mln | $0,0 mln | −100,0% | — | — | — | 4,4% |
| KORU Medical Systems, Inc. KRMD | $157 mln | $41,1 mln | 22,2% | −7,2% | — | — | 3,1% |
| Neuronetics, Inc. STIM | $154 mln | $149 mln | 99,2% | −21,1% | −41,4% | — | 1,4% |
| LENSAR, Inc. LNSR | $140 mln | $58,4 mln | 9,2% | −42,1% | — | — | 0,8% |
| Pulmonx Corp LUNG | $77,7 mln | $90,5 mln | 8,0% | −59,3% | −196,6% | — | 2,7% |
| Microbot Medical Inc. MBOT | $65,4 mln | — | — | — | — | — | 3,4% |
| RenovoRx, Inc. RNXT | $61,0 mln | $1,1 mln | 2.511,6% | −1.114,0% | — | — | 1,6% |
| TELA Bio, Inc. TELA | $55,4 mln | $80,3 mln | 15,8% | −42,0% | −239,8% | — | 4,5% |
| Sensus Healthcare, Inc. SRTS | $48,6 mln | $27,5 mln | −34,3% | −37,5% | — | — | 2,8% |
| Spectral AI, Inc. MDAI | $46,2 mln | $19,7 mln | −33,6% | −43,8% | — | — | 4,0% |
| Nexgel, Inc. NXGL | $45,3 mln | $11,4 mln | 31,5% | −29,3% | −56,0% | — | 5,7% |
| SANUWAVE Health, Inc. SNWV | $44,9 mln | $44,1 mln | 35,0% | 11,2% | 42,5% | 5,7x | 1,5% |
| Xtant Medical Holdings, Inc. XTNT | $39,6 mln | $134 mln | 14,2% | 5,4% | 11,5% | — | 9,5% |
| Nephros Inc NEPH | $39,2 mln | $18,8 mln | 32,7% | 6,1% | — | 22,1x | 0,3% |
| InspireMD, Inc. NSPR | $38,0 mln | $9,0 mln | 28,1% | −552,6% | — | — | 1,3% |
| CVRx, Inc. CVRX | $37,7 mln | $56,7 mln | 10,4% | −90,5% | −308,4% | — | 3,6% |
| DarioHealth Corp. DRIO | $35,2 mln | $22,4 mln | −17,3% | −163,9% | −39,9% | 0,6x | 10,6% |
| Retractable Technologies Inc RVP | $17,4 mln | $38,3 mln | 15,8% | −55,3% | −23,0% | — | 0,3% |
| PAVmed Inc. PAVM | $13,6 mln | $0,1 mln | −97,6% | −30.712,7% | — | 2,0x | 5,9% |
| Cerenome, Inc. CNSY | $11,3 mln | $5,2 mln | −10,5% | −293,5% | — | 0,1x | 6,3% |
| Modular Medical, Inc. MODD | $9,5 mln | — | — | — | — | — | 8,4% |
| NEUROONE MEDICAL TECHNOLOGIES Corp NMTC | $8,0 mln | $9,1 mln | 163,5% | −46,5% | — | — | 6,2% |
| Sintx Technologies, Inc. SINT | $7,7 mln | $1,0 mln | −64,7% | −1.053,1% | — | — | 3,7% |
| Femasys Inc FEMY | $5,0 mln | $2,3 mln | 40,8% | −767,0% | — | 0,9x | 3,8% |
| enVVeno Medical Corp NVNO | $4,5 mln | — | — | — | — | — | 3,8% |
| Sonoma Pharmaceuticals, Inc. SNOA | $4,3 mln | $19,5 mln | 36,7% | −12,6% | −211,8% | — | 3,5% |
| Vivos Therapeutics, Inc. VVOS | $2,4 mln | $17,4 mln | 16,0% | −114,1% | — | — | 0,9% |
| Co-Diagnostics, Inc. CODX | $2,4 mln | $0,6 mln | −84,1% | −8.058,7% | — | — | 4,3% |
| Intelligent Bio Solutions Inc. INBS | $2,3 mln | $4,2 mln | 38,1% | −299,1% | — | — | 5,6% |
| Glucotrack, Inc. GCTK | $2,0 mln | — | — | — | — | — | 32,7% |
| Aethlon Medical Inc AEMD | $1,9 mln | — | — | — | — | 0,2x | 2,7% |
| Beyond Air, Inc. XAIR | $1,5 mln | $7,7 mln | 107,3% | −378,2% | — | 0,1x | 9,1% |
| INVO Fertility, Inc. IVF | $1,5 mln | $6,8 mln | 4,7% | −105,8% | −94,7% | 0,0x | 7,0% |
| Bluejay Diagnostics, Inc. BJDX | $1,2 mln | — | — | — | — | 0,8x | 7,0% |
| HeartBeam, Inc. BEATW | $0,7 mln | — | — | — | — | — | 22,6% |
| Profusa, Inc. PFSA | $0,0 mln | — | — | — | — | 0,0x | 17,7% |
| Tenon Medical, Inc. TNON | $0,0 mln | $3,9 mln | 20,4% | −324,3% | — | — | 1,8% |
| Pulse Biosciences, Inc. PLSE | — | $0,4 mln | — | −21.982,6% | — | — | 0,6% |
| Brainsway Ltd. BWAY | — | $52,2 mln | 27,3% | 8,3% | — | — | �� |
| Apyx Medical Corp APYX | — | $52,8 mln | 9,9% | −12,2% | −25,1% | — | 1,7% |
| PolyPid Ltd. PYPD | — | — | — | — | −468,5% | — | �� |
| QTREX Quantum Ltd. QTEX | — | $0,3 mln | — | −4.713,8% | — | — | �� |
| Nyxoah SA NYXH | — | — | — | — | — | — | �� |
| Lucid Diagnostics Inc. LUCD | — | $4,7 mln | 8,3% | −1.054,8% | — | — | 25,4% |
| Picard Medical, Inc. PMI | — | $4,9 mln | 12,5% | −268,4% | — | — | 3,8% |
| Polyrizon Ltd. PLRZ | — | — | — | — | — | — | �� |
| SeaStar Medical Holding Corp ICU | — | $1,2 mln | 814,1% | −986,6% | — | — | 15,4% |
| Accuray Inc ARAY | — | $402 mln | −12,3% | −6,6% | −14,0% | — | 2,9% |
| Baird Medical Investment Holdings Ltd BDMD | — | $22,5 mln | −39,2% | −113,7% | −50,7% | — | �� |
| Pulsenmore Ltd. PLSM | — | $11,6 mln | 344,1% | — | — | — | �� |
| Autonomix Medical, Inc. AMIX | — | $0,0 mln | — | — | — | — | 3,2% |
| Flyte Aviation, Inc. VJET | — | $0,8 mln | 95,0% | −2.581,6% | −166,3% | — | 1,0% |
Health Care Equipment · 29
| Bedrijf | Beurswaarde | Omzet | Groei | Oper. marge | ROIC | K/W | Dag |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories ABT | $181,2 mld | $44,3 mld | 5,7% | 18,2% | 11,2% | 29,0x | 1,2% |
| Intuitive Surgical ISRG | $159,0 mld | $10,1 mld | 20,5% | 29,3% | 20,9% | 54,8x | 1,9% |
| Medtronic MDT | $122,6 mld | $36,4 mld | 8,4% | 17,8% | 7,7% | 23,4x | 1,2% |
| Stryker SYK | $118,6 mld | $25,1 mld | 11,2% | 19,5% | 11,3% | 31,8x | 0,0% |
| Boston Scientific BSX | $67,4 mld | $20,1 mld | 19,9% | 18,0% | 9,6% | 18,5x | 0,7% |
| Becton Dickinson BDX | $54,7 mld | $21,8 mld | 8,2% | 11,8% | 5,5% | 59,9x | 0,8% |
| Edwards Lifesciences EW | $51,4 mld | $6,1 mld | 11,6% | 20,8% | 15,7% | 51,2x | 1,1% |
| Idexx Laboratories IDXX | $44,4 mld | $4,3 mld | 10,4% | 31,6% | 57,3% | 39,4x | 1,1% |
| ResMed | RMD | $36,9 mld | $5,7 mld | 9,9% | 33,4% | 26,7% | — | 0,1% |
| GE HealthCare GEHC | $32,7 mld | $20,6 mld | 4,8% | 13,4% | 13,3% | 17,1x | 0,0% |
| Dexcom DXCM | $30,4 mld | $4,7 mld | 15,6% | 19,6% | 44,9% | 30,9x | 0,5% |
| Steris STE | $22,7 mld | $5,9 mld | 8,7% | 18,6% | 9,6% | 28,4x | 0,0% |
| Zimmer Biomet ZBH | $19,0 mld | $8,2 mld | 7,2% | 13,3% | 4,9% | 23,9x | 0,3% |
| Revvity RVTY | $17,7 mld | $2,9 mld | 3,7% | 12,5% | 3,3% | 76,0x | 0,9% |
| Baxter International BAX | $13,1 mld | $11,2 mld | 5,7% | −2,7% | −1,4% | — | 1,4% |
| Penumbra PEN | $12,8 mld | $1,4 mld | 17,5% | 13,5% | 18,8% | 79,7x | 0,2% |
| Globus Medical GMED | $11,2 mld | $2,9 mld | 16,7% | 16,3% | 11,0% | 20,9x | 0,3% |
| Glaukos GKOS | $10,5 mld | $507 mln | 32,3% | −39,3% | — | — | 1,2% |
| Insulet PODD | $10,3 mld | $2,7 mld | 30,7% | 17,5% | 20,4% | 27,9x | 0,6% |
| Bruker BRKR | $8,8 mld | $3,4 mld | 2,1% | 2,0% | 0,9% | — | 0,5% |
| LivaNova LIVN | $4,6 mld | $1,4 mld | 10,7% | 14,4% | 12,8% | 23,9x | 0,5% |
| Integer ITGR | $4,3 mld | $1,9 mld | 8,0% | 11,9% | 6,6% | 34,7x | 0,0% |
| LeMaitre Vascular LMAT | $2,1 mld | $250 mln | 13,5% | 27,2% | 25,5% | 29,6x | 1,0% |
| Inspire Medical Systems INSP | $2,1 mld | $912 mln | 13,6% | 5,6% | 14,2% | 15,7x | 2,1% |
| CONMED CNMD | $1,5 mld | $1,4 mld | 5,2% | 7,5% | 3,7% | — | 0,4% |
| Enovis ENOV | $1,2 mld | $2,2 mld | 6,7% | −50,0% | −26,9% | — | 2,4% |
| Artivion AORT | $1,1 mld | $441 mln | 13,6% | 7,7% | 3,9% | — | 2,8% |
| Integra Lifesciences IART | $936 mln | $1,6 mld | 1,5% | −30,2% | −22,0% | 70,1x | 3,4% |
| AdaptHealth AHCO | $819 mln | $3,2 mld | −0,5% | 2,8% | 2,1% | — | 2,4% |
Biotechnology · 22
| Bedrijf | Beurswaarde | Omzet | Groei | Oper. marge | ROIC | K/W | Dag |
|---|---|---|---|---|---|---|---|
| AbbVie ABBV | $505,9 mld | $61,2 mld | 8,6% | 24,7% | 15,7% | 80,7x | 0,2% |
| Amgen AMGN | $239,0 mld | $36,8 mld | 10,0% | 24,7% | 14,4% | 27,3x | 1,8% |
| Gilead Sciences GILD | $194,0 mld | $29,4 mld | 2,4% | 34,0% | 23,0% | — | 0,7% |
| Vertex Pharmaceuticals VRTX | $133,7 mld | $12,0 mld | 8,9% | 34,8% | 31,5% | 30,5x | 2,1% |
| Regeneron Pharmaceuticals REGN | $85,3 mld | $14,3 mld | 1,0% | 25,0% | 12,7% | 19,9x | 1,7% |
| Moderna MRNA | $79,6 mld | $1,9 mld | −39,9% | −158,1% | −65,4% | — | 1,2% |
| Biogen BIIB | $37,2 mld | $9,9 mld | 2,2% | — | 7,3% | 27,0x | 1,2% |
| United Therapeutics UTHR | $26,9 mld | $3,2 mld | 10,6% | 46,9% | — | 21,0x | 0,5% |
| Roivant Sciences ROIV | $26,3 mld | $8,3 mln | −71,6% | −6.235,7% | −62,6% | — | 2,6% |
| Incyte INCY | $23,9 mld | $5,1 mld | 21,2% | 29,5% | 79,4% | 16,3x | 1,0% |
| Exelixis EXEL | $16,8 mld | $2,3 mld | 7,0% | 37,6% | 64,9% | 20,3x | 1,2% |
| Halozyme HALO | $15,2 mld | $1,4 mld | 37,6% | 33,6% | 19,2% | 36,6x | 0,9% |
| Neurocrine Biosciences NBIX | $14,9 mld | $2,9 mld | 21,5% | 21,6% | 25,6% | 20,9x | 0,4% |
| BioMarin Pharmaceutical BMRN | $10,9 mld | $3,2 mld | 12,9% | 12,7% | 5,8% | 151,2x | 1,2% |
| Krystal Biotech KRYS | $9,6 mld | $389 mln | 33,9% | 41,5% | 43,6% | 39,0x | 2,7% |
| Arrowhead Pharmaceuticals ARWR | $8,3 mld | $829 mln | 23.258,2% | 11,9% | — | — | 0,6% |
| Ligand Pharmaceuticals LGND | $6,6 mld | $268 mln | 60,4% | 15,3% | 4,9% | 32,3x | 1,4% |
| ADMA Biologics ADMA | $2,5 mld | $510 mln | 19,6% | 37,5% | 39,5% | 15,3x | 2,5% |
| Fortrea FTRE | $2,2 mld | $2,7 mld | 1,0% | −32,0% | −36,2% | — | 1,2% |
| Harmony Biosciences HRMY | $2,1 mld | $869 mln | 21,5% | 24,0% | 48,9% | 11,7x | 0,3% |
| Repligen RGEN | — | $738 mln | 16,4% | 7,5% | 2,4% | — | 1,0% |
| Cytokinetics CYTK | — | $88,0 mln | 376,6% | −695,4% | — | — | 1,8% |
Services-Medical Laboratories · 22
| Bedrijf | Beurswaarde | Omzet | Groei | Oper. marge | ROIC | K/W | Dag |
|---|---|---|---|---|---|---|---|
| Natera, Inc. NTRA | $57,9 mld | $2,3 mld | 35,9% | −13,4% | −34,2% | — | 0,6% |
| Guardant Health, Inc. GH | $22,5 mld | $982 mln | 32,9% | −44,5% | −170,1% | — | 3,8% |
| Caris Life Sciences, Inc. CAI | $9,1 mld | $812 mln | 97,0% | 5,6% | 22,7% | 3,8x | 0,9% |
| BillionToOne, Inc. BLLN | $5,9 mld | $305 mln | 100,0% | 5,3% | 37,2% | 103,6x | 2,0% |
| GRAIL, Inc. GRAL | $5,7 mld | $147 mln | 17,2% | −382,0% | — | — | 4,3% |
| RadNet, Inc. RDNT | $5,5 mld | $2,0 mld | 11,5% | 3,0% | 2,9% | — | 0,1% |
| Veracyte, Inc. VCYT | $3,9 mld | $517 mln | 16,0% | 11,2% | — | 34,2x | 4,1% |
| CareDx, Inc. CDNA | $3,7 mld | $380 mln | 13,8% | −8,1% | — | 33,4x | 0,1% |
| Celcuity Inc. CELC | $3,6 mld | — | — | — | — | — | 0,5% |
| Personalis, Inc. PSNL | $1,7 mld | $69,6 mln | −17,7% | −126,4% | — | — | 0,2% |
| Castle Biosciences Inc CSTL | $1,0 mld | $344 mln | 3,7% | −12,4% | −18,6% | — | 0,3% |
| Fulgent Genetics, Inc. FLGT | $563 mln | $323 mln | 13,8% | −28,2% | — | — | 0,6% |
| Biodesix Inc BDSX | $218 mln | $88,5 mln | 24,1% | −31,5% | −77,1% | — | 11,5% |
| Exagen Inc. XGN | $176 mln | $66,6 mln | 19,7% | −21,1% | −136,6% | — | 2,8% |
| Sera Prognostics, Inc. SERA | $102 mln | $0,1 mln | 5,2% | −45.066,7% | — | — | 0,5% |
| American Shared Hospital Services AMS | $8,7 mln | $28,1 mln | −0,9% | −12,8% | −7,5% | — | 0,0% |
| Aclarion, Inc. ACON | $4,8 mln | $0,1 mln | 65,6% | −9.316,2% | — | — | 0,3% |
| Advanced Biomed Inc. ADVB | $4,0 mln | $0,1 mln | — | −4.885,2% | — | 0,6x | 8,4% |
| BioNexus Gene Lab Corp BGLC | $2,9 mln | $7,4 mln | −21,9% | −39,9% | — | — | 0,0% |
| YD Bio Ltd YDES | — | $0,6 mln | 16,9% | −883,3% | — | — | �� |
| Burning Rock Biotech Ltd BNR | — | $75,1 mln | 4,7% | −10,2% | −72,1% | — | �� |
| MDxHealth SA MDXH | — | $108 mln | 19,8% | −13,4% | −32,5% | — | �� |
Pharmaceuticals · 21
| Bedrijf | Beurswaarde | Omzet | Groei | Oper. marge | ROIC | K/W | Dag |
|---|---|---|---|---|---|---|---|
| Eli Lilly LLY | $1,14 bln | $65,2 mld | 44,7% | — | 40,8% | 42,7x | 2,5% |
| Johnson & Johnson JNJ | $646,0 mld | $94,2 mld | 6,1% | — | 28,6% | 40,0x | 1,4% |
| Merck MRK | $358,8 mld | $65,0 mld | 1,3% | — | 24,8% | 115,3x | 1,3% |
| AstraZeneca AZN | $267,9 mld | $58,7 mld | 8,6% | 23,4% | 16,8% | — | 0,6% |
| Pfizer PFE | $171,1 mld | $62,6 mld | −1,7% | — | 7,3% | 39,5x | 1,3% |
| Bristol Myers Squibb BMY | $125,9 mld | $48,2 mld | −0,2% | — | 15,2% | 13,5x | 2,4% |
| Teva Pharmaceuticals TEVA | $45,9 mld | $17,3 mld | 4,3% | 12,5% | 10,5% | 65,7x | 2,0% |
| Zoetis ZTS | $33,8 mld | $9,5 mld | 2,3% | — | 29,3% | 13,3x | 1,2% |
| Viatris VTRS | $20,9 mld | $14,3 mld | −3,0% | −18,6% | −7,1% | — | 2,6% |
| Jazz Pharmaceuticals JAZZ | $14,9 mld | $4,3 mld | 4,9% | −10,1% | −4,2% | 14,6x | 0,3% |
| Elanco ELAN | $11,4 mld | $4,7 mld | 6,2% | — | −0,1% | — | 0,7% |
| Corcept Therapeutics CORT | $10,2 mld | $761 mln | 12,8% | 5,9% | 15,7% | — | 20,1% |
| Alkermes ALKS | $7,6 mld | $1,5 mld | −5,3% | 17,2% | — | 114,8x | 1,2% |
| Amneal Pharmaceuticals AMRX | $6,7 mld | $3,0 mld | 8,1% | 13,1% | 16,1% | 41,6x | 0,5% |
| Indivior INDV | $4,3 mld | $1,2 mld | 4,3% | 21,2% | — | 12,4x | 2,4% |
| Acadia Pharmaceuticals ACAD | $3,4 mld | $1,1 mld | 11,9% | 9,8% | — | 8,8x | 2,9% |
| Bausch Health Companies BHC | $2,4 mld | $10,3 mld | 6,7% | 17,7% | 4,5% | — | 0,8% |
| ANI Pharmaceuticals ANIP | $1,6 mld | $883 mln | 43,8% | 12,6% | 15,9% | 15,7x | 1,5% |
| Innoviva INVA | $1,5 mld | $411 mln | 14,7% | 39,8% | 17,9% | 5,0x | 1,9% |
| Amphstar Pharmaceuticals AMPH | $1,1 mld | $720 mln | −1,7% | 19,5% | 9,9% | 14,9x | 3,5% |
| Collegium Pharmaceutical COLL | $746 mln | $781 mln | 23,6% | 23,0% | 53,4% | 18,5x | 2,3% |
Electromedical & Electrotherapeutic Apparatus · 20
| Bedrijf | Beurswaarde | Omzet | Groei | Oper. marge | ROIC | K/W | Dag |
|---|---|---|---|---|---|---|---|
| TransMedics Group, Inc. TMDX | $2,9 mld | $605 mln | 37,1% | 17,9% | — | 18,3x | 1,8% |
| Axogen, Inc. AXGN | $2,0 mld | $225 mln | 20,2% | −3,5% | −4,6% | — | 3,8% |
| Ceribell, Inc. CBLL | $1,0 mld | $89,1 mln | 36,1% | −65,6% | — | — | 1,0% |
| InMode Ltd. INMD | $914 mln | $370 mln | −6,2% | 23,0% | — | 9,8x | 0,6% |
| CapsoVision, Inc CV | $349 mln | $13,6 mln | 15,3% | −188,3% | — | 2,2x | 2,8% |
| Electromed, Inc. ELMD | $229 mln | $73,8 mln | 15,3% | 18,8% | — | 20,3x | 1,9% |
| Edap Tms Sa FOCL | $156 mln | $70,5 mln | 1,6% | −35,0% | −91,5% | — | 0,5% |
| Stereotaxis, Inc. STXS | $102 mln | $32,4 mln | 20,3% | −68,3% | — | — | 2,2% |
| Vivani Medical, Inc. VANI | $96,7 mln | $0,0 mln | — | — | — | — | 1,8% |
| Neuraxis, INC NRXS | $89,7 mln | $3,6 mln | 32,9% | −219,4% | — | — | 2,6% |
| Hyperfine, Inc. HYPR | $72,3 mln | $13,6 mln | 5,2% | −273,4% | −494,9% | — | 0,2% |
| Nexalin Technology, Inc. NXL | $39,3 mln | $0,3 mln | 78,8% | −2.782,1% | — | — | 8,4% |
| Precision Optics Corporation, Inc. POCI | $36,9 mln | $31,5 mln | 65,2% | −11,1% | −23,4% | — | 2,4% |
| Qt Imaging Holdings, Inc. QTI | $33,4 mln | $18,9 mln | 287,9% | −23,4% | −57,1% | — | 4,5% |
| Iridex Corp IRIX | $13,0 mln | $52,7 mln | 8,2% | −4,9% | — | — | 2,2% |
| ENDRA Life Sciences Inc. NDRA | $11,9 mln | — | — | — | — | — | 0,4% |
| Outset Medical, Inc. OM | $0,1 mln | $119 mln | 5,1% | −55,8% | −97,2% | — | 1,7% |
| electroCore, Inc. ECOR | $0,1 mln | $32,0 mln | 27,2% | −41,1% | — | — | 4,9% |
| Nuwellis, Inc. NUWE | $0,1 mln | $8,3 mln | −5,4% | −134,3% | — | 0,0x | 34,0% |
| iTonic Holdings Ltd ITOC | — | $0,5 mln | 16,7% | −991,8% | — | — | �� |
Health Care Services · 16
| Bedrijf | Beurswaarde | Omzet | Groei | Oper. marge | ROIC | K/W | Dag |
|---|---|---|---|---|---|---|---|
| CVS Health CVS | $120,3 mld | $402,1 mld | 7,9% | 1,2% | 2,9% | 24,6x | 1,1% |
| Cigna CI | $81,0 mld | $274,9 mld | 11,2% | 3,4% | 11,7% | 12,7x | 2,8% |
| Quest Diagnostics DGX | $27,1 mld | $11,0 mld | 11,8% | 14,1% | 9,5% | 24,1x | 0,6% |
| Labcorp LH | $27,0 mld | $14,0 mld | 7,3% | 9,9% | 8,2% | 27,2x | 0,3% |
| BrightSpring Health Services BTSG | $13,2 mld | $12,9 mld | 28,2% | 2,3% | 5,3% | 36,2x | 1,2% |
| DaVita DVA | $12,1 mld | $13,6 mld | 6,5% | 15,0% | 17,6% | 15,1x | 1,3% |
| Chemed CHE | $6,8 mld | $2,5 mld | 4,1% | 13,4% | 27,3% | 25,8x | 1,4% |
| Hims & Hers Health HIMS | $6,4 mld | $2,3 mld | 59,0% | 4,5% | 19,0% | — | 4,9% |
| Sotera Health SHC | $5,2 mld | $1,2 mld | 5,7% | — | 6,7% | 31,8x | 0,2% |
| Concentra Group Holdings Parent CON | $5,0 mld | $2,2 mld | 13,9% | 15,4% | 14,9% | 25,3x | 1,8% |
| Lifestance Health LFST | $5,0 mld | $1,4 mld | 13,9% | 1,7% | 1,2% | 99,5x | 2,9% |
| CorVel CRVL | $4,3 mld | $959 mln | 7,0% | — | — | 37,3x | 0,0% |
| Addus HomeCare ADUS | $2,3 mld | $1,4 mld | 23,2% | 9,7% | 9,4% | 21,3x | 0,7% |
| Amn Healthcare Services AMN | $1,9 mld | $2,7 mld | −8,5% | −2,0% | −2,8% | 17,8x | 2,5% |
| Alignment Healthcare ALHC | $1,7 mld | $3,9 mld | 46,1% | 0,4% | — | 42,4x | 4,4% |
| Tempus AI TEM | $13,5 mln | $1,3 mld | 83,4% | −19,9% | — | — | 6,0% |
Orthopedic, Prosthetic & Surgical Appliances & Supplies · 16
| Bedrijf | Beurswaarde | Omzet | Groei | Oper. marge | ROIC | K/W | Dag |
|---|---|---|---|---|---|---|---|
| Establishment Labs Holdings Inc. ESTA | $1,9 mld | $211 mln | 27,1% | −18,5% | −15,8% | — | 0,4% |
| Cadre Holdings, Inc. CDRE | $1,3 mld | $610 mln | 7,5% | 11,0% | 9,2% | 37,5x | 1,8% |
| Anteris Technologies Global Corp. AVR | $571 mln | $1,9 mln | −29,2% | −4.908,2% | — | — | 2,2% |
| Sanara MedTech Inc. SMTI | $284 mln | $103 mln | 19,0% | 7,1% | 16,3% | — | 0,2% |
| Inogen Inc INGN | $192 mln | $349 mln | 3,9% | −8,7% | — | — | 0,9% |
| Lakeland Industries Inc LAKE | $95,3 mln | $193 mln | 70,7% | −8,1% | −8,3% | — | 3,9% |
| NutriBand Inc. NTRB | $70,0 mln | $2,0 mln | −4,8% | −408,4% | — | — | 0,9% |
| Envoy Medical, Inc. COCH | $62,0 mln | $0,2 mln | 7,1% | −9.240,7% | — | — | 0,1% |
| Alpha Pro Tech Ltd APT | $57,5 mln | $59,1 mln | 2,3% | 6,5% | — | 13,9x | 0,5% |
| Myomo, Inc. MYO | $51,7 mln | $40,9 mln | 25,7% | −35,2% | −268,8% | — | 0,8% |
| Milestone Scientific Inc. MLSS | $28,4 mln | $9,0 mln | 4,0% | −63,5% | — | — | 2,1% |
| Lifeward Ltd. LFWD | $16,9 mln | $22,0 mln | −14,1% | −89,3% | — | — | 4,2% |
| Bone Biologics Corp BBLG | $0,7 mln | — | — | — | — | — | 2,7% |
| Jin Medical International Ltd. ZJYL | — | $20,7 mln | −12,0% | 2,9% | 2,8% | — | �� |
| Cuprina Holdings (Cayman) LTD CUPR | — | $0,0 mln | 5,5% | −9.673,0% | −178,5% | — | �� |
| Regentis Biomaterials Ltd. RGNT | — | — | — | — | — | — | �� |
Medicinal Chemicals & Botanical Products · 14
| Bedrijf | Beurswaarde | Omzet | Groei | Oper. marge | ROIC | K/W | Dag |
|---|---|---|---|---|---|---|---|
| Definium Therapeutics, Inc. DFTX | $3,9 mld | — | — | — | — | — | 0,9% |
| Trulieve Cannabis Corp. TRLV | $2,0 mld | $1,2 mld | −0,4% | 12,1% | 9,1% | — | 4,6% |
| Cronos Group Inc. CRON | $1,3 mld | $147 mln | 24,6% | −11,9% | — | 17,6x | 2,8% |
| Tilray Brands, Inc. TLRY | $375 mln | $915 mln | 11,5% | −6,9% | −3,3% | — | 4,1% |
| Usana Health Sciences Inc USNA | $258 mln | $925 mln | 8,3% | 4,0% | — | — | 3,9% |
| Niagen Bioscience, Inc. NAGE | $200 mln | $129 mln | 29,9% | 12,6% | — | 13,5x | 3,6% |
| Fitlife Brands, Inc. FTLF | $82,7 mln | $15,9 mln | −75,3% | 18,6% | — | 43,9x | 1,5% |
| biote Corp. BTMD | $30,6 mln | $192 mln | −2,5% | 18,5% | 146,1% | 10,7x | 1,8% |
| Mannatech Inc MTEX | $16,3 mln | $108 mln | −8,3% | −0,4% | — | — | 1,3% |
| Natural Alternatives International Inc NAII | $7,3 mln | $143 mln | 9,7% | −13,2% | — | — | 0,8% |
| SNDL Inc. SNDL | — | $677 mln | 0,7% | −0,7% | — | — | �� |
| Aurora Cannabis Inc ACB | — | $232 mln | 11,7% | — | — | — | �� |
| Glass House Brands Inc. GLAS | — | $182 mln | −9,4% | −9,1% | −11,0% | — | �� |
| MediWound Ltd. MDWD | — | $17,0 mln | −16,1% | −149,0% | — | — | �� |
In Vitro & In Vivo Diagnostic Substances · 14
| Bedrijf | Beurswaarde | Omzet | Groei | Oper. marge | ROIC | K/W | Dag |
|---|---|---|---|---|---|---|---|
| Neogen Corp NEOG | $2,7 mld | $870 mln | −2,7% | −2,5% | −0,6% | — | 1,8% |
| Celldex Therapeutics, Inc. CLDX | $2,3 mld | $1,5 mln | −78,0% | −18.599,8% | — | — | 1,0% |
| Intellia Therapeutics, Inc. NTLA | $1,5 mld | $67,7 mln | 16,9% | −651,7% | — | — | 0,4% |
| QuidelOrtho Corp QDEL | $938 mln | $2,7 mld | −1,9% | −33,7% | −15,7% | — | 1,9% |
| Achieve Life Sciences, Inc. ACHV | $607 mln | — | — | — | — | — | 0,2% |
| Myriad Genetics Inc MYGN | $552 mln | $825 mln | −1,6% | −47,0% | −90,4% | — | 1,0% |
| Alpha Teknova, Inc. TKNO | $344 mln | $40,5 mln | 7,4% | −41,9% | −22,1% | — | 4,4% |
| Insight Molecular Diagnostics Inc. IMDX | $104 mln | $4,1 mln | 115,6% | −1.260,8% | — | — | 0,4% |
| Immucell Corp /De/ ICCC | $94,2 mln | $27,6 mln | 4,3% | 6,0% | 4,0% | 146,4x | 1,8% |
| Biomerica Inc BMRA | $5,5 mln | $4,5 mln | −16,2% | −119,5% | — | — | 0,0% |
| Cardio Diagnostics Holdings, Inc. CDIO | $5,0 mln | $0,0 mln | −57,6% | −43.811,5% | — | — | 0,9% |
| Q/C Technologies, Inc. QCLS | $3,9 mln | — | — | — | — | 0,0x | 10,7% |
| Volitionrx Ltd VNRX | $1,6 mln | $1,7 mln | 40,0% | −1.258,5% | — | — | 3,0% |
| Anbio Biotechnology NNNN | — | $8,6 mln | 5,6% | 66,7% | — | — | �� |
Life Sciences Tools & Services · 13
| Bedrijf | Beurswaarde | Omzet | Groei | Oper. marge | ROIC | K/W | Dag |
|---|---|---|---|---|---|---|---|
| Thermo Fisher Scientific TMO | $250,0 mld | $44,6 mld | 3,9% | 17,4% | 9,1% | 36,2x | 0,4% |
| Danaher DHR | $162,9 mld | $24,6 mld | 2,9% | 19,1% | 6,1% | 37,7x | 0,3% |
| Agilent Technologies A | $49,0 mld | $6,9 mld | 6,7% | 21,3% | 16,5% | 34,1x | 0,5% |
| IQVIA IQV | $47,4 mld | $16,3 mld | 5,9% | 13,4% | 9,5% | 34,7x | 0,4% |
| Waters WAT | $44,6 mld | $3,2 mld | 7,0% | 25,4% | 21,0% | — | 0,4% |
| Illumina ILMN | $41,2 mld | $4,3 mld | −0,7% | 18,6% | 20,3% | 50,3x | 0,0% |
| Mettler Toledo MTD | $33,7 mld | $4,0 mld | 4,0% | — | 50,5% | 37,6x | 0,9% |
| Medpace MEDP | $19,0 mld | $2,5 mld | 20,0% | 21,1% | — | 37,2x | 2,3% |
| Charles River Laboratories CRL | $16,6 mld | $4,0 mld | −0,9% | 0,6% | 0,4% | — | 1,7% |
| Avantor AVTR | $11,7 mld | $6,6 mld | −3,4% | −3,8% | −2,1% | — | 0,8% |
| Bio-Techne TECH | $11,4 mld | $1,2 mld | −0,4% | 20,7% | 9,2% | — | 0,1% |
| Bio-Rad Laboratories BIO | $9,9 mld | $2,6 mld | 0,7% | 1,8% | 0,5% | 46,3x | 1,8% |
| Azenta AZTA | $1,7 mld | $594 mln | 3,6% | −4,5% | — | — | 1,4% |
Services-Health Services · 11
| Bedrijf | Beurswaarde | Omzet | Groei | Oper. marge | ROIC | K/W | Dag |
|---|---|---|---|---|---|---|---|
| Privia Health Group, Inc. PRVA | $3,0 mld | $2,1 mld | 22,3% | 1,6% | — | 101,9x | 2,1% |
| GeneDx Holdings Corp. WGS | $1,7 mld | $428 mln | 40,0% | −3,1% | −5,4% | — | 16,4% |
| Pennant Group, Inc. PNTG | $1,5 mld | $948 mln | 36,3% | 5,5% | 7,3% | 46,0x | 0,8% |
| U S Physical Therapy Inc /Nv USPH | $1,3 mld | $781 mln | 16,3% | 11,1% | 10,7% | — | 0,2% |
| InnovAge Holding Corp. INNV | $1,3 mld | $990 mln | 15,9% | 0,3% | 1,2% | — | 0,3% |
| Omada Health, Inc. OMDA | $1,2 mld | $260 mln | 53,2% | −4,6% | −123,7% | 17,7x | 0,2% |
| Strata Critical Medical, Inc. SRTA | $402 mln | $197 mln | 34,3% | −11,3% | — | 9,3x | 1,1% |
| DocGo Inc. DCGO | $26,8 mln | $322 mln | −47,7% | −55,3% | −150,9% | — | 0,4% |
| P3 Health Partners Inc. PIII | $13,9 mln | $1,5 mld | −2,8% | −18,5% | −229,2% | — | 5,0% |
| Agape ATP Corp ATPC | $1,4 mln | $1,5 mln | 15,2% | −213,6% | — | 1,1x | 1,8% |
| Alps Group Inc ALPS | — | $4,9 mln | 44,1% | −41,8% | — | — | �� |
Health Care Supplies · 10
| Bedrijf | Beurswaarde | Omzet | Groei | Oper. marge | ROIC | K/W | Dag |
|---|---|---|---|---|---|---|---|
| Alcon ALC | $34,8 mld | $10,4 mld | 4,9% | 13,1% | 4,6% | — | 0,7% |
| West Pharmaceutical Services WST | $28,0 mld | $3,1 mld | 6,3% | 19,0% | 18,7% | 50,2x | 0,5% |
| Cooper Companies COO | $11,8 mld | $4,1 mld | 5,1% | 16,7% | 4,3% | 21,0x | 0,7% |
| Align Technology ALGN | $11,0 mld | $4,0 mld | 0,9% | 13,5% | 13,3% | 26,9x | 0,6% |
| Lantheus LNTH | $6,7 mld | $1,5 mld | 0,5% | 20,2% | 22,7% | 24,2x | 0,3% |
| Haemonetics HAE | $5,4 mld | $1,3 mld | −2,0% | 11,8% | 6,7% | 57,3x | 2,0% |
| ICU Medical ICUI | $4,2 mld | $2,2 mld | −6,3% | 1,9% | 0,7% | 140,0x | 1,0% |
| Envista NVST | $3,9 mld | $2,7 mld | 8,3% | 8,0% | 3,2% | 40,7x | 1,5% |
| Dentsply Sirona XRAY | $1,9 mld | $3,7 mld | −3,0% | −11,5% | −9,9% | — | 0,7% |
| BioLife Solutions BLFS | — | $96,2 mln | 28,9% | −17,3% | −4,8% | — | �� |
Health Care Facilities · 8
| Bedrijf | Beurswaarde | Omzet | Groei | Oper. marge | ROIC | K/W | Dag |
|---|---|---|---|---|---|---|---|
| HCA Healthcare HCA | $106,3 mld | $75,6 mld | 7,1% | — | 22,3% | 16,2x | 0,4% |
| Tenet Health THC | $22,5 mld | $21,3 mld | 3,1% | 16,5% | 18,3% | 10,4x | 0,8% |
| Encompass Health EHC | $12,4 mld | $5,9 mld | 10,5% | — | 15,8% | 20,2x | 1,5% |
| Universal Health Services UHS | $11,2 mld | $17,4 mld | 9,7% | 11,5% | 13,1% | 7,6x | 0,7% |
| Ensign Group ENSG | $10,4 mld | $5,1 mld | 18,7% | 8,4% | 19,7% | 27,5x | 1,5% |
| Option Care Health OPCH | $4,9 mld | $5,6 mld | 13,0% | 6,0% | 11,4% | 24,4x | 0,2% |
| Acadia Healthcare ACHC | $2,9 mld | $3,3 mld | 5,0% | — | −16,0% | — | 1,2% |
| Astrana Health ASTH | $1,9 mld | $3,2 mld | 56,4% | 2,5% | 4,2% | 45,1x | 1,5% |
Services-Commercial Physical & Biological Research · 8
| Bedrijf | Beurswaarde | Omzet | Groei | Oper. marge | ROIC | K/W | Dag |
|---|---|---|---|---|---|---|---|
| Absci Corp ABSI | $1,4 mld | $2,8 mln | −38,2% | −4.297,0% | — | — | 2,0% |
| OmniAb, Inc. OABI | $600 mln | $18,7 mln | −29,3% | −369,5% | — | — | 2,5% |
| Nrc Health NRC | $483 mln | $137 mln | −4,0% | 16,4% | 16,5% | 0,4x | 2,6% |
| OneMedNet Corp ONMD | $273 mln | $1,4 mln | 111,4% | −711,3% | — | — | 4,1% |
| Maxcyte, Inc. MXCT | $150 mln | $33,0 mln | −14,5% | −157,1% | — | — | 2,1% |
| bioAffinity Technologies, Inc. BIAF | $14,6 mln | $6,2 mln | −34,2% | −171,6% | — | — | 11,7% |
| iSpecimen Inc. ISPC | $1,1 mln | $1,9 mln | −79,2% | −465,4% | — | 0,0x | 1,9% |
| IB Acquisition Corp. IBAC | — | — | — | — | — | — | 0,0% |
Managed Health Care · 7
| Bedrijf | Beurswaarde | Omzet | Groei | Oper. marge | ROIC | K/W | Dag |
|---|---|---|---|---|---|---|---|
| UnitedHealth UNH | $378,8 mld | $447,6 mld | 11,8% | 4,2% | 11,2% | 26,9x | 1,6% |
| Elevance Health ELV | $95,7 mld | $199,1 mld | 12,5% | 3,6% | 15,2% | 18,7x | 1,2% |
| Humana HUM | $50,9 mld | $129,7 mld | 10,1% | 2,1% | 25,7% | 45,0x | 0,3% |
| Centene CNC | $34,9 mld | $194,8 mld | 19,4% | −3,9% | −26,4% | — | 1,5% |
| Molina Healthcare MOH | $10,8 mld | $45,4 mld | 11,8% | 1,7% | — | — | 3,5% |
| Oscar Health OSCR | $10,3 mld | $11,7 mld | 27,5% | −3,4% | — | 23,8x | 7,0% |
| HealthEquity HQY | $8,7 mld | $1,3 mld | 9,5% | 24,6% | 8,9% | 37,5x | 3,0% |
Services-Misc Health & Allied Services, Nec · 7
| Bedrijf | Beurswaarde | Omzet | Groei | Oper. marge | ROIC | K/W | Dag |
|---|---|---|---|---|---|---|---|
| Progyny, Inc. PGNY | $2,4 mld | $1,3 mld | 10,4% | 6,6% | — | 31,5x | 0,5% |
| agilon health, inc. AGL | $1,5 mld | $5,9 mld | −2,1% | −7,8% | — | — | 0,6% |
| Viemed Healthcare, Inc. VMD | $403 mln | $270 mln | 20,5% | 8,5% | 11,5% | 27,2x | 1,2% |
| Cryo Cell International Inc CCEL | $35,9 mln | $31,6 mln | −1,3% | 1,5% | — | — | 0,8% |
| BioRestorative Therapies, Inc. BRTX | $28,7 mln | $0,4 mln | −10,3% | −4.350,0% | — | — | 8,0% |
| Mangoceuticals, Inc. MGRX | $4,0 mln | $0,5 mln | −26,0% | −3.954,5% | — | — | 5,1% |
| Charming Medical Ltd MCTA | — | $4,8 mln | −22,7% | −0,6% | −2,2% | — | �� |
Services-Offices & Clinics Of Doctors Of Medicine · 6
| Bedrijf | Beurswaarde | Omzet | Groei | Oper. marge | ROIC | K/W | Dag |
|---|---|---|---|---|---|---|---|
| Teladoc Health, Inc. TDOC | $1,1 mld | $2,5 mld | −1,5% | −10,4% | — | — | 0,3% |
| Starling Oncology, Inc. STLN | $691 mln | $503 mln | 27,8% | −7,2% | −101,4% | — | 2,9% |
| SBC Medical Group Holdings Inc SBC | $542 mln | $174 mln | −15,5% | 38,9% | 34,5% | 11,0x | 7,2% |
| LifeMD, Inc. LFMD | $102 mln | $194 mln | 25,3% | −4,0% | — | 8,5x | 1,8% |
| Airsculpt Technologies, Inc. AIRS | $84,9 mln | $152 mln | −15,8% | −7,6% | −6,7% | — | 4,0% |
| Concord Medical Services Holdings Ltd CCM | — | $64,1 mln | 20,1% | −56,8% | −19,2% | — | �� |
Health Care Technology · 5
| Bedrijf | Beurswaarde | Omzet | Groei | Oper. marge | ROIC | K/W | Dag |
|---|---|---|---|---|---|---|---|
| Veeva Systems VEEV | $53,3 mld | $3,2 mld | 16,3% | 28,7% | — | 52,9x | 0,2% |
| Solventum SOLV | $14,8 mld | $8,3 mld | 0,9% | 26,2% | 20,4% | 10,5x | 2,3% |
| Doximity DOCS | $6,4 mld | $645 mln | 13,1% | 33,3% | 91,3% | 39,3x | 0,9% |
| Certara CERT | $1,6 mld | $419 mln | 8,8% | 5,0% | 0,9% | — | 2,4% |
| HealthStream HSTM | $1,0 mld | $304 mln | 4,3% | 6,7% | — | 48,8x | 1,6% |
Wholesale-Drugs, Proprietaries & Druggists' Sundries · 5
| Bedrijf | Beurswaarde | Omzet | Groei | Oper. marge | ROIC | K/W | Dag |
|---|---|---|---|---|---|---|---|
| Herbalife Ltd. HLF | $1,4 mld | $5,0 mld | 0,9% | 9,5% | 35,4% | 8,6x | 2,8% |
| Nu Skin Enterprises, Inc. NUS | $233 mln | $1,5 mld | −14,3% | 4,4% | 6,8% | — | 2,6% |
| Cosmos Health Inc. COSM | $15,6 mln | $65,3 mln | 19,9% | −25,6% | −61,6% | — | 3,2% |
| HWH International Inc. ESYN | $12,8 mln | $0,9 mln | −30,8% | — | — | — | 3,4% |
| DataMeds AI, Inc. MEDS | $5,7 mln | $23,3 mln | 28,7% | −401,7% | −338,4% | — | 3,0% |
Health Care Distributors · 4
| Bedrijf | Beurswaarde | Omzet | Groei | Oper. marge | ROIC | K/W | Dag |
|---|---|---|---|---|---|---|---|
| McKesson MCK | $119,3 mld | $403,4 mld | 12,4% | 1,5% | — | 26,8x | 1,1% |
| Cencora COR | $64,2 mld | $321,3 mld | 9,3% | 0,8% | — | 24,6x | 2,2% |
| Cardinal Health CAH | $59,1 mld | $254,2 mld | 14,2% | 1,0% | — | — | 2,4% |
| Henry Schein HSIC | $9,7 mld | $13,2 mld | 4,0% | 5,0% | 7,5% | 24,8x | 1,2% |
Ophthalmic Goods · 4
| Bedrijf | Beurswaarde | Omzet | Groei | Oper. marge | ROIC | K/W | Dag |
|---|---|---|---|---|---|---|---|
| Bausch & Lomb Corp BLCO | $6,2 mld | $5,1 mld | 6,5% | 2,2% | 0,8% | — | 0,2% |
| Staar Surgical Co STAA | $1,2 mld | $239 mln | −23,7% | −38,3% | — | — | 0,5% |
| RxSight, Inc. RXST | $208 mln | $134 mln | −3,9% | −35,8% | — | — | 1,2% |
| Innovative Eyewear Inc LUCY | $5,6 mln | $2,7 mln | 62,7% | — | — | — | 0,7% |
Services-Nursing & Personal Care Facilities · 3
| Bedrijf | Beurswaarde | Omzet | Groei | Oper. marge | ROIC | K/W | Dag |
|---|---|---|---|---|---|---|---|
| Brookdale Senior Living Inc. BKD | $2,5 mld | $3,2 mld | 2,2% | 0,4% | 0,3% | — | 1,1% |
| Healthcare Services Group Inc HCSG | $1,8 mld | $1,8 mld | 7,1% | — | — | 17,1x | 2,1% |
| Sonida Senior Living, Inc. SNDA | $1,6 mld | $381 mln | 25,2% | — | — | — | 0,1% |
Services-General Medical & Surgical Hospitals, Nec · 3
| Bedrijf | Beurswaarde | Omzet | Groei | Oper. marge | ROIC | K/W | Dag |
|---|---|---|---|---|---|---|---|
| Surgery Partners, Inc. SGRY | $2,0 mld | $3,3 mld | 6,2% | 11,8% | 6,3% | — | 0,9% |
| Ardent Health, Inc. ARDT | $1,8 mld | $6,3 mld | 6,0% | — | — | 22,3x | 0,7% |
| Community Health Systems Inc CYH | $399 mln | $12,5 mld | −1,2% | 11,9% | 15,9% | 1,6x | 0,3% |
Services-Skilled Nursing Care Facilities · 2
| Bedrijf | Beurswaarde | Omzet | Groei | Oper. marge | ROIC | K/W | Dag |
|---|---|---|---|---|---|---|---|
| PACS Group, Inc. PACS | $7,7 mld | $5,3 mld | 29,3% | 5,9% | 18,9% | 27,9x | 0,3% |
| National Healthcare Corp NHC | $3,7 mld | $1,5 mld | 16,1% | 8,5% | 9,5% | 26,5x | 2,9% |
X-Ray Apparatus & Tubes & Related Irradiation Apparatus · 2
| Bedrijf | Beurswaarde | Omzet | Groei | Oper. marge | ROIC | K/W | Dag |
|---|---|---|---|---|---|---|---|
| Butterfly Network, Inc. BFLY | $1,8 mld | $97,6 mln | 19,0% | −88,5% | — | — | 0,7% |
| Nano-X Imaging Ltd. NNOX | — | $13,0 mln | 15,4% | −600,8% | −65,9% | — | �� |
Services-Home Health Care Services · 1
| Bedrijf | Beurswaarde | Omzet | Groei | Oper. marge | ROIC | K/W | Dag |
|---|---|---|---|---|---|---|---|
| Aveanna Healthcare Holdings, Inc. AVAH | $3,0 mld | $2,4 mld | 20,2% | 10,5% | 19,7% | 10,6x | 0,5% |
Services-Hospitals · 1
| Bedrijf | Beurswaarde | Omzet | Groei | Oper. marge | ROIC | K/W | Dag |
|---|---|---|---|---|---|---|---|
| Pediatrix Medical Group, Inc. MD | $2,4 mld | $1,9 mld | −4,9% | 10,9% | 16,6% | 14,0x | 0,9% |
